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ABSTRACT
Inflammatory wounds, both chronic and acute, lead to increased morbidity and
mortality rates, especially in the elderly population. The annual healthcare cost for chronic
wound care alone is over $39B in the US and the demographic of susceptible patients is
steadily increasing due to an aging population and lifestyle-related diseases (e.g.,
hyperlipidemia, obesity, and type 2 diabetes). In fact, many chronic wounds currently
have a worse 5-year outlook than certain types of cancers. This shows the need for
expediting the wound healing process in such a way that compresses inflammatory
signaling and encourages wound resolution without sacrificing pathogen removal and
tissue integrity. A patient’s “lipid fingerprint” of sphingolipids and eicosanoids has recently
emerged as a unique field of study, dubbed “lipidomics”, to better explain the complex
molecular milieu of the mammalian inflammatory response in many common diseases
such as wound healing and sepsis. Based on a decade of prior research from our lab and
others, we hypothesize that specific changes in sphingolipid and eicosanoid profiles can
enhance the proficiency of wound healing and quell the severity of inflammatory
response.
We propose the mechanism of C1P production by the enzyme CERK and
subsequent interaction with cPLA2α as principal therapeutic targets for shifting eicosanoid
production toward wound resolution (e.g., elevated HETEs). The research contained in
this dissertation builds upon previous work from our lab but expands the purview of acute
wound healing to the onset of inflammation and offers unique insight into neutrophil

xii

migration velocity and cellular behaviors (e.g., “N1” vs “N2”). Furthermore, we
demonstrate that 5-oxo-ETE signals through a murine OXER1 receptor to modulate PPP
activity, and that in vivo post-injury C1P inhibition is a viable approach to accelerating the
wound healing process. Using a mixture of animal models and ex vivo cell culture assays
combined with modern lipidomic techniques and traditional biological analyses we
validate the physiological benefits of post-injury C1P inhibition and the anti-inflammatory
effect of 5-oxo-ETE signaling through OXER1. These novel findings present promising
therapeutic targets for future clinical studies regarding acute and chronic wound healing,
sepsis, and other inflammatory diseases.
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CHAPTER ONE: INTRODUCTION
Abstract
The phosphorylated sphingolipid Ceramide-1-phosphate (C1P) has long been
implicated as a dynamic bioactive agent. Over two decades of research has begun to
characterize various regulatory roles for C1P from mammalian inflammatory response
and wound healing to cellular proliferation and survival. As a metabolite of the intricately
balanced “sphingolipid rheostat”, C1P stands as a crucial physiological regulator of both
upstream and downstream mechanisms. This introduction serves as an overview of what
is known and unknown about C1P’s role in cellular processes vital to disease and
physiology. Additionally, we’ll discuss potential clinical roles for C1P in cancer treatment,
wound therapy, and pre-disease diagnosis. While many questions remain regarding C1P
metabolism and the extent of signaling factors targeted by this bioactive lipid, new
technologies and methodologies show great promise to discern key targets, signaling
pathways, and physiologies regulated by C1P.
Reprinted by permission from Springer Nature Switzerland: Bioactive Ceramides in
Health and Disease, Advances in Experimental Medicine and Biology 1159, (The Role of
Ceramide 1-Phosphate in Inflammation, Cellular Proliferation, and Wound Healing;
Berwick, Dudley, Maus, and Chalfant), 2019.

1

Ceramide-1-Phosphate
Ceramide 1-phosphate (C1P), a sphingoid analog of phosphatidic acid, is one of
the metabolites in the sphingomyelin (SM) cycle (Fig. 1.1). C1P is formed from ceramide
by the action of a specific ceramide kinase (CERK), which is related to, but distinct from
the sphingosine kinases (SphKs) that synthesize sphingosine 1-phosphate (S1P)
(Sugiura et al. 2002; Wijesinghe et al. 2007). Indeed, CERK was found to contain the five
conserved domains (C1–C5) previously identified for SphK1 and 2, but CERK showed
complete substrate specificity for ceramide with no enzymatic activity observed for
sphingosine. In animal tissues, the substrate ceramide is derived primarily from the
hydrolysis of SM and the de novo sphingolipid biosynthesis pathway, which begins via
the initial condensation of serine and palmitoyl-CoA (Chalfant and Spiegel 2005). Due to
the interconvertibility of ceramide, C1P, sphingosine and S1P, the SM cycle is also
referred to as a “sphingolipid rheostat” that can regulate immune cell function, cell
survival, and inflammatory response (Maceyka et al. 2002). C1P has been explicitly
implicated in propagation and regulation of the wound healing and inflammatory
processes (Stephenson et al. 2017).
In regard to inflammatory processes, the production of arachidonic acid (AA) is an
early response to various inflammatory agonists such as mechanical trauma associated
with wounding. AA liberation by phospholipases is the initial rate-limiting step in the
biosynthesis of eicosanoids (Clark et al. 1995), which are well-established mediators of
inflammation (Chalfant and Spiegel 2005). The major phospholipase that regulates
eicosanoid synthesis in response to inflammatory cytokines is group IVA cytosolic
phospholipase A2 alpha (cPLA2α).
2

A decade of research from our laboratory has demonstrated that C1P produced by
CERK is a proximal mediator of PLA2 activation and subsequent AA release in response
to inflammatory cytokines, interleukin-1 beta cytokine (IL-1β) and tumor necrosis factor
alpha (TNFα), calcium ionophore, and ATP. Activation and translocation of cPLA2α in
cells requires the association of the enzyme with membranes in a calcium-dependent
manner via a Ca2+-dependent lipid binding (CaLB) domain located near the N-terminus.
Published findings from our laboratory demonstrated that C1P is a direct activator of
cPLA2α through specific interaction with the C2/CaLB domain (Pettus et al. 2004; Lamour
et al. 2009), which enhances the membrane affinity for cPLA2α via decreasing the
dissociation rate of the enzyme from phosphatidylcholine (PC)-rich membranes
(Subramanian et al. 2007). These results coupled with the previous findings that
CERK/C1P pathway is required for cPLA2α activation in response to calcium ionophore
and inflammatory cytokines (Pettus et al. 2003) demonstrated that C1P was a “missing
link” in the eicosanoid biosynthetic and regulatory pathways (Lamour and Chalfant 2005).

3
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Figure 1.1. Simplified schema demonstrating the interconvertibility of ceramide, C1P,
sphingosine, and S1P in the sphingomyelin cycle, creating the “sphingolipid rheostat.”
Reprinted by permission from Springer Nature Switzerland: Bioactive Ceramides in
Health and Disease, Advances in Experimental Medicine and Biology 1159, (The Role of
Ceramide 1-Phosphate in Inflammation, Cellular Proliferation, and Wound Healing;
Berwick, Dudley, Maus, and Chalfant), 2019.

The Biosynthesis of Ceramide 1-Phosphate in Mammalian Cells
In mammalian cells, the precursor molecule of C1P, ceramide, is synthesized in
the endoplasmic reticulum (ER) and transferred to the Golgi apparatus by either ceramide
transport protein (CERT) in an active manner or passive vesicular trafficking (Lamour et
al. 2007; Boath et al. 2008; Wijesinghe et al. 2010). Like activated cPLA2α, CERK is
primarily associated with membranes such as the cytosolic surface of the trans-Golgi
4

network (TGN) as well as early and late endosomes (Lamour et al. 2007). This allows
C1P to be generated in the appropriate cellular compartment for recruitment of cPLA 2α in
response to inflammatory agonists (Carre et al. 2004). CERK utilizes ATP as the
phosphate donor and requires calcium ion interaction via a calmodulin-binding motif
(Sugiura et al. 2002). In mammals, the only established pathway for C1P production is
through phosphorylation of ceramide by CERK. CERK recognizes ceramide in a
stereospecific manner, requiring a minimum of a 4-carbon acyl chain and a 4-5 trans
double bond (Wijesinghe et al. 2005). Additionally, the free hydrogen of the secondary
amide group and the sphingoid chain are necessary for substrate recognition by CERK.
While the saturation state of the fatty acyl chain appears not to affect specificity,
methylation of the primary or secondary hydroxyl groups decreased the phosphorylative
activity of CERK. Combined, these factors indicate a very high specificity for substrate
recognition by CERK for ceramide and not chemically similar compounds such as
sphingosine, diacylglycerol, and dihydroceramide.
A membrane-bound C1P transport protein designated “CPTP” is also an essential
component in the metabolism of C1P (Fig. 1.2). CPTP operates in a C1P concentrationdependent manner to maintain a constant level of C1P in the Golgi membrane and
transfers the lipid to the plasma membrane or other cellular compartments as required
(Simanshu et al. 2013). Our laboratory in collaboration with Brown, Patel, and colleagues
demonstrated that C1P is in constant flux within the cell and is not catabolized locally
requiring CPTP to move C1P to specific cellular locations for rapid catabolism. For
example, in CPTP-depleted cells, marked increases in AA levels and their downstream
metabolites indicated C1P accumulation at the Golgi/TGN, which was confirmed by

5

sphingo-lipidomics (Mishra et al. 2018). Additionally, siRNA-induced knockdown of
CERK, and hence C1P production, restored the levels of C1P, AA, and eicosanoids to
normal cells that were initially elevated by CPTP depletion (Simanshu et al. 2013).
Conversely, AA and eicosanoid levels decreased upon overexpression of wild-type CPTP
signifying rapid transport of C1P from the Golgi to other areas of the cell, which also led
to a concomitant decrease in the total intracellular levels of C1P. The complete picture of
C1P catabolism is not fully understood, but the current hypothesis suggests that lipid
phosphate phosphatases (LPPs), specifically LPPs 1-3, may catabolize C1P to ceramide
following transport of the lipid by CPTP to the plasma membrane (Figs. 1.1 & 1.2).
However, the roles of other enzymes such as ceramidases remain possible contributors
in the possible conversion of C1P to S1P.
In regard to the anabolism of C1P, research suggests that at least one additional
anabolic pathway for C1P generation exists in mammalian cells as the genetic ablation
of CERK only reduces the cellular context of C1P by approximately 50% (Mietla et al.
2014). One possible explanation for a significant amount of C1P remaining in these cells
is the reported generation of C1P via acylation of sphingosine 1-phosphate (S1P) by an
unknown lipid acylase (Binoda et al. 2004). Indeed, unpublished findings from our
laboratory have shown that the exogenous addition of

32P-labeled

S1P to cells leads to

the production of C1P, but the percentage of total cellular C1P attributed to this anabolic
pathway is currently unknown and understudied.

6

Figure 1.2. Ceramide-1-phosphate metabolism. Sphingolipids are synthesized to
produce ceramide in the endoplasmic reticulum (ER) via de novo biosynthesis. Ceramide
(Cer) is transported from the ER throughout the cell, but primarily to the Golgi apparatus
by either passive vesicular trafficking (PVT) or actively via the ceramide transport protein
(CERT). Ceramide is then phosphorylated by CERK to create C1P, which is then
transported to the plasma membrane and additional cellular membranes by CPTP. C1P
may then be hydrolyzed to ceramide by lipid phospholipid phosphatases (LPPs).
Reprinted by permission from Springer Nature Switzerland: Bioactive Ceramides in
Health and Disease, Advances in Experimental Medicine and Biology 1159, (The Role of
Ceramide 1-Phosphate in Inflammation, Cellular Proliferation, and Wound Healing;
Berwick, Dudley, Maus, and Chalfant), 2019.
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Another possible route of C1P anabolism is via a sphingomyelinase D (SMase D),
which is found in the venom of the brown recluse spider and related species. Indeed, this
form of SMase D hydrolyzes SM to produce C1P and cyclic C1P (Hoeferlin et al. 2013),
which is associated with an inflammatory response mediated by prostaglandins and AA
following the bite from this species of spider. Although a SMase D activity has not been
described in mammalian cells, endogenous C1P production by an enzyme with SMase D
activity is possible. To our knowledge, neither PLD1 nor PLD2 have been extensively
studied for enzymatic activity towards SM, and even minimal activity of these enzymes
toward SM would produce significant amounts of C1P as the levels of this bioactive lipid
are very low in most cellular contexts. As with the examination of an S1P acylase, this
research area of lipid metabolism is also understudied.

The Generation of Eicosanoids and Induction of the Inflammatory Response by
Ceramide-1-Phosphate
At the membrane, bioactive lipids serve to anchor cPLA2α, and the enzyme then
proceeds to release sn2-unsaturated fatty acids (AA, eicosapentaenoic acid (EPA),
docosahexaenoic acid (DHA)) from membrane phospholipids. Through interactions with
cyclooxygenases, cytochrome P450, or lipoxygenases, AA is then converted into proinflammatory mediators (Fig. 1.3) while released EPA and DHA are converted to primarily
anti-inflammatory lipid mediators (Stephenson et al. 2017). Research in over a dozen
different cell types has shown that nanomolar concentrations of C1P induce AA release
and the synthesis of eicosanoids (Stephenson et al. 2017, Pettus et al. 2003). Further
exploration demonstrated that this effect was also lipid-specific as the closely related
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lipids, phosphatidic acid, ceramide, diacylglycerol, and S1P had either minimal or no
effects on AA release and prostanoid synthesis. Experimentation with siRNA
downregulation of cPLA2α demonstrated that the induction of AA release by C1P was
strictly dependent on cPLA2α activation (Pettus et al. 2004). Indeed, the colocalization of
cPLA2α and C1P to the cellular membrane is required for the production of eicosanoids
linked to inflammation (Lamour et al. 2007).
Inflammation is a localized immune response as a consequence to infection or
injury. The inflammatory response is achieved in part by eicosanoid synthesis, resulting
in the formation of prostaglandins and leukotrienes. Common non-steroidal antiinflammatory drugs, such as ibuprofen, target these prostaglandin biosynthetic enzymes
known as cyclooxygenases (COX-1 and -2). Inhibition of these enzymes blocks the
conversion of AA to inflammatory prostaglandins (Botting and Botting 2004; Pettus et al.
2005). As first noted earlier in this chapter, the production of these eicosanoids is initially
mediated via cPLA2α, which is activated by translocation of the enzyme to the cell
membranes requiring direct association with C1P (Fig. 1.3). Indeed, cPLA2α is
translocated to the membrane of the Golgi and binds to PC in a calcium-dependent
manner. C1P directly interacts with cPLA2α and decreases the dissociation rate of the
enzyme from PC-rich membranes, thereby increasing the residence time of the enzyme
and subsequent hydrolysis of zwitterionic phospholipids at the sn-2 position producing
AA and driving eicosanoid biosynthesis (Lamour and Chalfant, 2008). Our laboratory
showed the high specificity of the physical interaction between C1P and the C2 domain
of cPLA2α. For example, other structurally similar lipids (e.g., ceramide and S1P) were
incapable of activating cPLA2α in vitro or in cells as well as bind to the enzyme with
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substantial affinity (Hoeferlin et al. 2013). The requirement for C1P association with
cPLA2α to activate eicosanoid synthesis was further explored by our laboratory, and the
allosteric activity of C1P was substantiated to regulate cPLA2α association with PC-rich
vesicles by the novel β-groove of cPLA2α. Specific amino acids in this region were
identified to be required for bioactive sphingolipid interaction with C1P. This assertion was
demonstrated by inducing mutations in the basic amino acids in the β-groove (Stahelin et
al. 2007). Indeed, mutations in Arg57, Lys58, and Arg59 within this domain resulted in
inhibition of the activation of cPLA2α by C1P. Further exploration by Stahelin and
colleagues revealed that cPLA2α /C1P interaction also required Arg61, and His62 (Ward
et al. 2013). These studies were the first to assess a specific interaction site for C1P
interaction with a specific target protein.
C1P also regulates the inflammatory response via modulation of cytokine
maturation/secretion, specifically TNFα. Excessive TNFα is found in sepsis, thereby
resulting in an accumulation of downstream inflammatory components and subsequent
uncontrolled immune responses. Our laboratory showed that CERK through the
production of C1P acts as a negative regulator in the production of TNFα by blocking the
proteolytic conversion of pro-TNFα to the active form of the cytokine (Lamour et al. 2011).
More specifically, isolates of BMDMs from CERK knockout mice presented with elevated
levels of TNFα and the activity of its proteolytic converting enzyme, TACE, in comparison
to wild type cells when challenged with the inflammatory agonist, lipopolysaccharide
(Goldsmith et al. 2011). The reduced TNFα secretion observed in the cells from the CERK
knockout mice could be reverted to wild type levels via re-expression of CERK (Lamour
et al. 2011). In mechanistic studies, our laboratory showed that C1P served to directly
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bind and inhibit TACE, and thus, the maturation of TNFα, but it is currently unknown as
to the exact location of these C1P binding sites although a consensus amino acid
sequence similar to the known C1P binding site in cPLA2α was apparent. This seemingly
opposing role for C1P in the inflammatory response is logical in which C1P both induces
the inflammatory response via activating cPLA2α and inducing eicosanoids, and also
limits the inflammation from cascading out of control by blocking the maturation and
secretion of TNFα.

Figure 1.3. Localization of C1P-cPLA2α interaction at the cellular membrane generates
AA-derived eicosanoids that tend to be pro-inflammatory mediators (indicated in red).
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Figure 1.3 (Continued): Downstream products of DHA and EPA-derived eicosanoids are
anti-inflammatory/pro-resolution (not shown). Reprinted by permission from Springer
Nature Switzerland: Bioactive Ceramides in Health and Disease, Advances in
Experimental Medicine and Biology 1159, (The Role of Ceramide 1-Phosphate in
Inflammation, Cellular Proliferation, and Wound Healing; Berwick, Dudley, Maus, and
Chalfant), 2019.

The Role of Ceramide 1-Phosphate in Cellular Proliferation
Of the many roles C1P plays in the regulation of cellular processes, major findings
promote the idea that survival, proliferation, and apoptosis are among those that have
been shown to impact human disease (Gómez-Muñoz et al. 2005; Mishra et al. 2019).
Where ceramide is involved in inducing apoptosis, C1P provides the opposite effect and
inhibits apoptosis. Indeed, our laboratory in collaboration with Spiegel and co-workers
showed that at low concentrations C1P had a positive impact on cellular proliferation
although high concentrations of C1P were cytotoxic to A549 lung carcinoma cells (Mitra
et al. 2007). Another study by Gómez-Muñoz and co-workers (2004) revealed the same
phenomenon in macrophages. This observed biphasic effect points to a “balancing
system” inside the cell as high levels of C1P induced apoptosis due to catabolism by
dephosphorylation creating increased levels of the apoptogenic sphingolipid, ceramide
(Mitra et al. 2007). Hence, if there is any deviation from this balance between C1P and
ceramide, the functioning metabolism of the cell may be compromised and lead to lethality
(Arana et al. 2010). This metabolic balancing act within the cell as well as the differential
partitioning of lipids added exogenously to cells makes definitive conclusions of cellular
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function for a specific sphingolipid, in many cases, elusive. Indeed, C1P and ceramides
are implicated in a multitude of pathways that make use of many different components
depending on concentration, location, and the type of cell being studied. This biochemical
conundrum likely explains many of the discrepancies and overlap in activity and functions
ascribed to these two bioactive lipid mediators in a number of published studies.
Regardless, specific and possibly overlapping signal transduction pathways ascribed as
regulated directly by C1P are discussed further in subsequent sections (Fig. 1.4).
Additionally, Gómez-Muñoz and co-workers have reported the possibility of cell
surface receptors recognizing and mediating C1P interaction. Indeed, many of the effects
of C1P on cell function (i.e., cellular proliferation) have been shown via exogenous C1P
as discussed previously in this chapter. By applying C1P exogenously in cell culture,
Gómez-Muñoz and co-workers observed stimulation of cell migration, a phenomenon
which is independent of the production of intracellular C1P. these findings suggested a
specific receptor for this biological function of C1P. Indeed, PKB and MAP kinases such
as extracellularly regulated kinase (ERK) play a large role in C1P-mediated cellular
migration, which may be linked to receptor activation (Granado et al. 2009). Thus, the
effects on cellular signaling pathways may be receptor mediated, and Gómez-Muñoz and
colleagues have provided strong evidence in this regard. In further investigations, a
synthetic C1P analog known as PCERA-1 was utilized to identify the specific receptors
that mediate C1P activity. Unfortunately, PCERA-1 was unable to interfere with C1P
binding to the cell surface receptor, alluding to the possibility that C1P and PCERA-1
bind to separate cell surface receptors (Katz et al. 2016). Overall, the role of C1P in
mediating cellular effects via activation of cell surface receptors is an area of intense
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investigation, but the lack of identifying the receptor has not yet allowed for wide-spread
acceptance of the model.

Figure 1.4. C1P induced cell proliferation and survival pathways. Ceramide from the de
novo and sphingomyelin hydrolysis pathways is converted into ceramide 1-phosphate
(C1P) via phosphorylation by CerK. Increased concentrations of synthesized C1P can
directly inhibit acid sphingomyelinase (A-SMase) and possibly serine palmitoyl
transferase (SPT) via Orm sensors that detect increased C1P levels. Exogenous and
endogenous C1P also influence cell proliferation and survival in a number of ways: (1)
C1P activates EGFR signaling and the phosphatidylinositol 3-kinase (PI3-K) pathway
either directly or indirectly, which induces cell survival and has also been shown to have
an inhibitory effect on A-SMase; (2) Annexin A2t binds directly to C1P and drives cellular
invasion and endothelial migration in the presence of calcium; and (3) C1P directly or
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Figure 1.4 (Continued): indirectly interacts with and activates ERK1/2 to increase cell
survival by enhancing the MAP kinase pathway. Individually, any one of these pathways
result in proliferation and survival, and co-activation of combinations of these survival
pathways could induce a heightened response. Reprinted by permission from Springer
Nature Switzerland: Bioactive Ceramides in Health and Disease, Advances in
Experimental Medicine and Biology 1159, (The Role of Ceramide 1-Phosphate in
Inflammation, Cellular Proliferation, and Wound Healing; Berwick, Dudley, Maus, and
Chalfant), 2019.

C1P and Acid Sphingomyelinase
Acid sphingomyelinase (A-SMase) is a lipid hydrolase that converts SM to
ceramide and phosphocholine (Wang et al. 2015). Deficiencies in this catabolic
sphingolipid enzyme are connected to a number of human diseases, from cardiovascular
and neurodegenerative to cancers. In regard to C1P signaling and A-SMase, a previous
study by Gómez-Muñoz and co-workers showed that apoptosis of primary bone marrowderived macrophages (BMDMs) was impeded in the presence of natural C1P. Apoptotic
BMDMs, a frequently used model to explore apoptosis, are known to have high levels of
A-SMase as well as ceramide, which blocks survival pathways in favor of apoptosis. In
opposition, the direct inhibition of A-SMase by C1P without the presence of growth
factors, and in conjunction with the activation of the PI3-K/AKT signaling pathway,
stimulates cell survival (Bornancin 2011). Indeed, the addition of C1P to the cell culture
medium proved to increase cell viability when compared to sham controls (Gómez-Muñoz
et al. 2005). C1P of differing chain lengths were also tested and showed increased
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viability, however not to the extent that of natural C1P (Gómez-Muñoz et al. 2005). Of
note, the anabolism of C1P from specific ceramide species stemming from the six known
ceramide synthases has not been examined, but interestingly, different chain lengths of
ceramide derived from specific ceramide synthases have been attributed to specific and
differing cell responses. For example, Ogretmen and co-workers have shown that D-eC16:0-ceramides produced by ceramide synthases 5 or 6 have anti-apoptotic properties,
but D-e-C18:0-ceramides, produced by ceramide synthases 1 and 4 are involved with
cellular death (Ponnusamy et al. 2010). Stiban and Perera reported interference of very
long chain ceramides (C22:0 and C24:1) on C16:0-induced channel formation and vice versa
(2015). Hence, one can hypothesize that different chain lengths of C1P may also be
responsible for specific cellular physiologies.
As stated above, A-SMase showed high activity in BMDMs (Gómez-Muñoz et al.
2005). In mechanistic studies, Gómez-Muñoz and coworkers demonstrated that in the
presence of C1P, A-SMase activity was inhibited. Furthermore, decreased levels of C1P
were observed in apoptotic cells giving credence to the idea that A-SMase was no longer
being inhibited by C1P, and C1P was an inhibitory factor for this pathway (Arana et al.
2010). Additional mechanistic studies demonstrated that inhibition of A-SMase occurs via
a direct physical interaction with C1P that prevents the accumulation of ceramide, and
thereby, contributes to the anti-apoptotic effect of C1P observed in mammalian cells. A
later study also found that serine palmitoyltransferase (SPT), which is the initial and ratelimiting enzyme in the generation of ceramide via the de novo sphingolipid biosynthetic
pathway, followed this pattern of antiapoptosis through inhibition by C1P causing
decreased levels of ceramide (Arana et al. 2010). To date, the mechanism by which C1P
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modulates SPT activity is unknown, but Orm proteins, known regulators of SPT activity
and sphingolipid feedback sensors, may play a role. Indeed, Orm proteins may act as
sensors for elevated C1P levels, and thereby, induce the inhibition of SPT to preserve the
sphingolipid rheostat, but how Orms are regulating the sphingolipid biosynthesis
pathways is still under intense investigation (Siow and Wattenberg 2012).

The Association of Ceramide1-Phosphate with the PI3-K/AKT, NF-kB, and Other
Survival Pathways
Another commonly studied cell survival mechanism involves the activation of the
PI3-K pathway by various growth factors through tyrosine kinase receptors. This lipid
kinase pathway plays major roles in regulating adhesion, motility, and survival.
Furthermore, mutations or amplifications of the PI3-K gene to produce constitutive
activation of the enzyme has shown the PI3-K pathway as oncogenic in many types of
cancers via apoptosis inhibition (Larsen and Minna 2011). Interestingly, C1P has been
reported to trigger mitogenesis through phosphorylation and activation of the PI3-K/AKT
(also known as PKB) pathway, whose downstream targets includes the stimulation of the
DNA binding activity of the transcription factor, nuclear factor κB (NF-κB) (Arana et al.
2010). Whether this is a direct or indirect interaction remains largely unknown. NF-κB,
like PI3-K, regulates cellular processes implicated in human cancers when constitutively
activated making it a possible target for cancer treatment (Dolcet et al. 2005). More
specifically, C1P stimulates binding of NF-κB to DNA through phosphorylation of IκB to
increase expression of cell proliferation marker regulators (e.g., Bcl-xL and GSK-3B).
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These are downstream targets of NF-κB that impact mitogenic proteins such as cyclin D1
and Myc, and thus, encourage cell proliferation (Arana et al. 2010).
Interestingly, there is a reported connection on the activation of PI3-K to the ASMase activity via the synthesis of phosphatidylinositol triphosphate (PIP3), a main
product of PI3-K. Specifically, PIP3 has an inhibitory effect on A-SMase. This secondary
inhibition may increase the effect of the direct physical interaction and subsequent
inactivation of A-SMase through C1P (Arana et al. 2010). Additionally, the effect of C1P
on proliferation stems from activation of the extracellularly regulated kinases 1 and 2
(ERK1/2). A likely mechanism of promoting cell survival through C1P could be its ability
to activate AKT and ERK1/2 paired with the ability of CERK to enhance epithelial growth
factor (EGF) effects via the EGF receptor in the activation of AKT and ERK1/2
phosphorylation (Mitra et al. 2007). In support of this hypothesis, when CERK is
downregulated in A549 lung adenocarcinoma cells, EGF-induced proliferation is blocked,
and the ability of EGF to induce the phosphorylation of AKT and ERK1/2 is also reduced
(Mitra et al. 2007). These data, combined with data showing that exogenous C1P can
activate AKT and ERK1/2, support the hypothesis that these additional kinases as well
as additional survival pathways outside of simple inhibition of A-SMase are involved in
C1P-induced proliferation (Mitra et al. 2007).
One possible additional pathway for C1P-induced proliferation was recently
reported. Specifically, Kester and co-workers showed that C1P also plays a role in cell
proliferation and invasion when bound to the annexin a2/protein p11 extracellular
heterotetrameric complex (A2t). Annexins are scaffolding proteins that regulate
phospholipid binding in the presence of calcium. The A2t complex acts as a “receptor
18

platform” for proteins, and when bound to exogenous C1P assists with endothelial cell
migration (Hankins et al. 2013). Interestingly, when endothelial invasion was tested in the
presence of either ceramide or S1P, there was only moderate migration in contrast to the
much more dramatic invasion induced by C1P. It was hypothesized that that C1P was
more effective at stimulating invasion due to selective binding with A2t, specifically the
p11 protein component. Indeed, C1P was demonstrated to bind directly to A2t with high
specificity while no interaction between A2t and S1P was detected. Ultimately, the ability
of the cell to invade was shown to require both p11 and annexin proteins bound to
exogenous C1P in a calcium-dependent manner (Hankins et al. 2013).

The Role of Ceramide 1-Phosphate in Wound Healing
Wound healing is a dynamic process involving four main phases: hemostasis,
inflammation, proliferation, and remodeling. During hemostasis, clotting factors work in
tandem with constricting blood vessels to decrease bleeding. As the hemostasis phase
ends, the wound transitions into the inflammatory phase, where vasodilation, increased
vascular permeability, and neutrophil and macrophage infiltration into the wound site
occur. After the wound has been cleared of foreign debris and prepped by the cells
involved in inflammation, the proliferation phase introduces fibroblasts and keratinocytes
into the wound to initiate wound closure and angiogenesis. The final phase of wound
healing is remodeling, where collagen is deposited and crosslinked, allowing new
epithelial layers to form (Clark 1988).
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The role of individual lipids and their regulation relevant to wound healing has been
studied for many decades. However, evaluation of lipids using lipidomics approaches has
only recently been possible and widely available to the research community, which is now
causing a resurgence of research into bioactive lipids as key mediators of underlying
mechanisms related to chronic wound development and progression. Lipidomics also
opens new avenues of risk assessment and appraisal of targeted therapeutics by
detecting “lipid fingerprints” associated with impaired wound healing before clinical
manifestations are evident. Indeed, a characteristic of impaired wound healing is an
imbalance between pro- and anti-inflammatory lipids (Dhall et al. 2015). For example,
prostaglandin E2 (PGE2) has been implicated in the inhibition of cell migration and
meandering during the acute wound healing process (White et al. 2005). Leukotrienes
are another class of eicosanoid that play a major role in the wound healing process. For
example, leukotriene B4 (LTB4) recruits neutrophils to areas containing damaged tissue
to initiate the inflammatory phase of the wound healing process, and the stalling of wound
healing at this stage is linked to chronic neutrophilia in the wound environment (Luo et al.
2017). Additionally, the impaired healing of pressure ulcers correlates with high levels of
pro-inflammatory eicosanoids such as LTD4, LTE4, and PGE2 which lead to excess
inflammation (Dhall et al. 2015), and the reduction of COX-2-derived eicosanoids (e.g.,
PGE2) has also been shown to improve the healing of pressure ulcers in mice (RomanaSouza et al. 2016). Furthermore, localized excess of PGE2 has been linked to delayed
wound healing and impaired fibroblast function (White et al. 2005). Lastly, PGE1, an antiinflammatory prostaglandin acting in opposition to the pro-inflammatory PGE2, was
approved in 2010 to treat human wounds.
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Additional reports indicate that the bioactive fraction in platelet-rich plasma (PRP)
for autologous wound therapy is the lipid component rather than the protein component
and is responsible for driving specific wound healing mechanisms at the cellular level.
Further, nutritional preparations containing pro-resolution lipids decrease the progression
of pressure ulcers (Hoeferlin et al. 2015). These studies present the possibility of altering
the lipid profile of PRP via diet or exogenous pathway manipulation of the SM cycle to
obtain a better healing outcome. Taken together, the accumulating evidence provides a
strong foundation for the premise that bioactive lipid mediators play key roles in the wound
healing process, and further study into multicentric and temporal approaches to treatment
may be warranted in manipulating these biosynthetic pathways for a positive clinical
outcome.
Recent studies have also shown C1P as a key regulator of bioactive eicosanoids
involved in wound healing. For example, a number of direct downstream products of C1P/
cPLA2α interaction were found to be increased in PRP from healthy individuals. In
particular, 5-, 12-, and 15-HETE, which have been shown to be mitogenic toward
fibroblasts, and PGF2α, which could be a contributing factor to the observed increase in
cell proliferation and improved wound healing. Overall, the scientific literature supports
key and distinct roles for AA-derived eicosanoids regulated by C1P in the wound healing
process and in its dysregulation and resultant “stalling” in the inflammatory phase. In this
pursuit, Gómez-Muñoz and co-workers are seeking to identify distinct macrophage
receptors that could be exploited to design sphingolipid mimics for exogenous use in the
treatment of inflammatory diseases (Katz et al. 2016). Further, our laboratory reported
that C1P derived from CERK negatively regulates the migration of fibroblasts. Importantly,
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C1P levels were elevated in the inflammatory phase, and subsequently decreased during
the proliferation and remodeling stages in human wound healing correlating with the
timing of enhanced fibroblast migration (Wijesinghe et al. 2014). Since the C1P/ cPLA2α
interaction is the “master regulator” of these downstream eicosanoids, research into the
specific timings and signaling mechanisms characteristic of optimal wound healing is vital
in the context of C1P production in the wound environment. Similarly, formation of distinct
lipid profiles (e.g., C1P, eicosanoids) may prove to be a critical method of early detection
and treatment of patients prone to impaired wound healing. Thus, the hypothesis as to a
role for the C1P/ cPLA2α interaction during the wound healing process provides “food for
thought” as to targeting this unique and specific interaction for the development of future
therapeutics to enhance healing outcomes.

Hypothesis and Specific Aims
The research presented in this dissertation aims to address two important scientific
questions. First, how do post-injury C1P levels modulate the proliferation and remodeling
phases of the acute wound healing process in mammals? Secondly, can C1P/cPLA2α
ablation produce an eicosanoid profile conducive to an anti-inflammatory, pro-resolution
healing phenotype? To address C1P’s influence on proliferation, we hypothesized that
C1P is a negative regulator of wound healing and that post-injury inhibition of CERKderived C1P would improve acute wound healing outcomes in mice. To address the
second scientific question, we hypothesized that mice with an ablated C1P-cPLA2α
interaction site would demonstrate enhanced neutrophil behaviors conducive to less
inflammatory response and increased wound resolution.
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There are two specific aims included in this dissertation. The first aim compares
post-injury oral administration of a novel CERK inhibitor to a whole-body CERK-knockout
mouse model to evaluate acute wound closure, fibroblast migration velocity, and
histological markers for wound maturation (e.g., fibroblast activation protein, Type I
collage). The second aim takes a closer look at the early stages of wound healing to
compare neutrophil behaviors between cPLA2α-KI and WT mice to elucidate seemingly
contradictory observations of neutrophilia and improved healing outcomes. A meticulous
effort was made to connect the influence of specific sphingolipid and eicosanoid species
to the modulation of processes vital to expedient wound healing.
Note to Reader: Portions of this chapter have been previously published in Bioactive
Ceramides in Health and Disease, Advances in Experimental Medicine and Biology,
2019, 1159: 65-77, and have been reproduced with permission from Springer Nature
Switzerland. Author Contributions: All authors (Berwick, Dudley, Maus, and Chalfant)
are considered co-first authors and contributed equally to the work.
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CHAPTER TWO: CERAMIDE KINASE REGULATES ACUTE WOUND HEALING BY
SUPPRESSING 5-oxo-ETE BIOSYNTHESIS AND SIGNALING VIA ITS RECEPTOR
OXER1.

Abstract
The bioactive sphingolipid, ceramide-1-phosphate (C1P), has been shown to
promote the inflammatory phase and inhibit the proliferation and remodeling stages of
wound repair via direct interaction with Group IVA cytosolic phospholipase A 2 (cPLA2α),
a regulator of eicosanoid biosynthesis that fine-tunes the behaviors of various cell types
during wound healing. However, the anabolic enzyme responsible for the production of
C1P that suppresses wound healing as well as bioactive eicosanoids and target receptors
that drive enhanced wound remodeling have not been characterized. In this study, we
determined that decreasing C1P activity via inhibitors or genetic ablation of the anabolic
enzyme ceramide kinase (CERK) significantly enhanced wound healing phenotypes.
Importantly, post-wounding inhibition of CERK enhanced the closure rate of acute
wounds, improved the quality of healing, and increased fibroblast migration via a “classswitch” in the eicosanoid profile. This switch also induced reduced pro-inflammatory
prostaglandins (e.g., PGE2) and increased levels of the hydroxyeicosatetraenoic acid
species 5-HETE and the downstream metabolite 5-oxo-ETE. Moreover, dermal
fibroblasts from mice with genetically ablated CERK showed enhanced wound healing
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markers, while blockage of the murine 5-oxo-ETE receptor (OXER1) inhibited the
enhanced migration phenotype of these cell models. Together, these studies reinforce
the vital roles eicosanoids play in the wound healing process and demonstrate a novel
role for CERK-derived C1P as a negative regulator of 5-oxo-ETE biosynthesis and the
activation of OXER1 in wound healing. These findings provide foundational pre-clinical
results for the use of CERK inhibitors to shift the balance from inflammation to resolution
and increase the healing rate of wounds.

Introduction
The wound healing cascade is a dynamic process involving four distinct yet
overlapping phases: hemostasis, inflammation, proliferation, and remodeling (Clark,
1988). Hemostasis is marked by vasoconstriction and the activation of clotting factors to
reduce blood loss (Versteeg et al. 2013). Inflammation quickly follows to eliminate
pathogens and external debris from the wound site (Diegelmann et al. 2004). Proliferation
begins once foreign bodies have been removed by neutrophils and macrophages,
allowing fibroblasts and keratinocytes to migrate into the wound site, ushering the
transition from the inflammatory immune response and into the proliferative and
angiogenetic phases (Koh and DiPietro 2011). Lastly, new epithelial layers are formed,
and collagen is crosslinked during the remodeling phase (Broughton et al. 2006). Key
factors in assessing wound maturation are the numbers and migration velocity of
incoming fibroblasts, presence of fibroblast activation protein (FAP), and the deposition
of collagen type I (Shultz et al. 2011).
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Our study focuses on the role of eicosanoids in wound healing, which are
specialized lipid mediators with reported roles in mammalian wound response and the
impairment of wound healing (Berwick et al. 2019). For example, impaired wounds
typically result from an imbalance between pro- and anti-inflammatory eicosanoids such
as prostaglandins and epoxyeicosatrienoic acids, respectively (Dhall et al. 2015).
Because of this, the blockade of COX-2-derived eicosanoids such as PGE2 is a long-used
clinical technique to reduce inflammation (Romana-Souza et al. 2016). Localized excess
of PGE2 is linked to delayed wound healing and inhibition of fibroblast function (White et
al. 2005), while various lipoxygenase-derived eicosanoids have been tied to increased
fibroblast chemotaxis and metabolic activity (Ruzicka 1990). Furthermore, fibroblast
chemotaxis during wound healing is influenced by eicosanoids through unique receptors
separate from peptide-mediated chemoattraction such as PDGF or EGF (Rieger et al.
1990). Overall, new technological advancements in small molecule analyses (e.g.,
lipidomics) (Stephenson et al. 2019) have identified a biochemical manifestation of
impaired wound healing: the development of an imbalance between pro- and antiinflammatory eicosanoids independent of peptide mediators.
The synthesis of eicosanoids begins with the initial rate-limiting step, the
generation of arachidonic acid (AA) via the activity of a phospholipase A 2 (PLA2) (Clark
et al. 1995). One of the major PLA2s involved in this initial step is group IVA cytosolic
PLA2 (cPLA2α), which our laboratory demonstrated is activated by direct binding to the
sphingolipid, ceramide-1-phosphate (C1P) (Pettus et al. 2004). For example, siRNA
technology to downregulate ceramide kinase (CERK), the enzyme responsible for C1P
formation, blocked cPLA2α activation, arachidonic acid (AA) release and eicosanoid

26

production in response to inflammatory cytokines, ATP, and calcium ionophore (Pettus et
al. 2003). Previous findings from the Chalfant Laboratory demonstrated that the specific
interaction site for C1P is localized to the calcium binding loop II of the C2 domain of
cPLA2α, specifically the cationic β-groove (Stehelin et al. 2007; Wijesinghe et al. 2009;
Ward et al. 2013). Mutagenesis of critical amino acids for C1P interaction within this site
inhibited the ability of cPLA2α to translocate in response to inflammatory agonists (Lamour
et al. 2009). These data suggest that CERK and its product, C1P, are required for the
activation of cPLA2α, and are thus major regulators of eicosanoid synthesis in cells. Our
laboratory also discovered that C1P is temporally regulated, increasing in the
inflammatory phase of human wound healing (Wijesinghe et al. 2014). Additional work by
our laboratory has also recently shown that the C1P:cPLA2α interaction negatively
regulates the migration of dermal fibroblasts and 5-HETE production, and genetic ablation
of this interaction enhanced acute wound healing in mice (MacKnight et al. 2019) (e.g.
enhanced wound tensile strength, increased collagen I deposition, reduced collagen III
deposition, and increased fibroblast wound infiltration).
In this study, our laboratory explored the source of ceramide-1-phosphate
associated with the negative regulation of dermal fibroblast migration and wound healing.
Specifically, we examined the hypothesis that inhibition of the formation of C1P via
targeting the anabolic enzyme, CERK, either by genetic manipulations or by a new
generation, small molecule inhibitors, will enhance the migration of murine dermal
fibroblasts in culture and into the acute wounds of mice as well as induce the
downregulation of PGE2 synthesis and upregulation of HETE production in murine dermal
fibroblasts. Using a novel CERK inhibitor (SYR382141) in comparison to a conventional
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and established CERK inhibitor (NVP-231) and genetically engineered mouse models
(GEMMs), either an ablated C1P interaction site (cPLA2α-KI) or CERK ablated (CERKKO), we show that inhibition/ablation of CERK confers a distinct lipid “fingerprint”
consistent with dermal fibroblasts that confers more rapid cell migration and accelerates
the transition from inflammation to proliferation. In expanded mechanistic studies, a
distinct role for the 5-HETE metabolite, 5-oxo-ETE, was shown to facilitate enhanced
fibroblast migration through a murine G protein-coupled oxoeicosatetraenoic receptor
(OXER1). Lastly, we found that the inhibition of CERK, post-wounding, conferred
enhanced wound healing and maturation providing a pre-clinical foundation to explore
human clinical applications. Overall, these studies show that CERK-derived C1P inhibits
the proliferation/remodeling stages of wound healing showing the therapeutic relevance
of CERK inhibitors in this paradigm.

Materials and Methods
SYR382141 Compound: A request to access the CERK inhibitor SYR382141 should be
made directly to the Neuroscience Drug Discovery Unit, Takeda California, San Diego,
CA, USA.

PCR-based Identification of WT, cPLA2α-KI, and CERK-KO:
Genotyping of WT, cPLA2α-KI, and CERK-KO mice was performed by first
collecting genomic DNA using an Accustart II genotyping kit followed by polymerase chain
reaction (PCR) as previously described by us (Paronetto et al. 2007; Gowda et al. 2021)
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using

the

following

primers:

KI:

PLA2

PLA2

TGAGGGTCGTGCTGTAGAGTTAG-3’;

KO:

TGCCAGATGTGAACTTACTTCCAG-3’;

58780-58757,
cre

(P1)

ATATCTCACGTACTGACGGTGGG-3’)

58534-58556,

primers
and

5’5’(5’(5’-

CCTGTTTCACTATCCAGGTTACGG-3’) (P2) (Fig. 2.1). 50ng of genomic DNA was used
for each reaction along with the following primer concentrations, KI: 0.2 µmol/L PLA2
58534-58556 (P1) 0.2 µmol/L PLA2 58780-58757 (P2) and CERK-KO: 0.2 µmol/L P1 and
0.2 µmol/L P2. The following reaction cycles were repeated 33 times, 94°C for 1 min, 59°C
for 1 min, and 72°C for 2 min. Reaction products expected are as follows cPLA2α-WT:
237bp, cPLA2α-KI: 412bp, CERK-WT: 207, and CERK-KO: 480bp and were examined
using a 2% agarose gel.

RT-qPCR Analysis of mRNA Expression:
RNA from WT and CERK-KO primary dermal fibroblasts was converted to cDNA
and used for quantitative PCR analysis using primers specific to the mouse Cerk gene
(Thermo) and mouse actin control (Thermo). Methods as previous described by us
(Chalfant et al. 2002; DeLigio et al. 2017; Caslin et al. 2019) (Fig. 2.1).
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Figure 2.1. Strategy and design of the novel CERK KO mice. (A) A schematic
representation of the inserted flanked loxP sites (“floxed”) and their associated BamH I
sites at the beginning of endogenous introns 5 and 6 used to generate the CERK knockout
(CERK-KO) mice used in this study. Mice possessing a floxed Cerk allele were bred to
mice expressing Cre recombinase in the germline (EIIa-cre homozygotes, JAX stock
#003724). Offspring were screened for the KO allele and confirmed by DNA sequencing.
Cre-mediated deletion of Cerk exon 6 (encoding amino acids 191-238) results in a
translational frame-shift with termination in exon 8. Mice carrying the KO allele were
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Figure 2.1. (continued) subsequently bred to C57BL/6J mice, and Cre-negative offspring
were selected to establish the CERK-KO line. (B) RNA from WT and CERK-KO primary
dermal fibroblasts was converted to cDNA and used for quantitative PCR analysis using
primers specific to the mouse Cerk gene. Samples were compared using ANOVA
followed by Tukey's post-hoc test. Data shown are means ± SD (n = 4, **p < 0.01). (C)
Genotypic analysis of WT, Floxed, and CERK-KO alleles was performed using genomic
DNA, analyzed via end point multiplex PCR using the following primers: Intron 5 forward
primer: 5’-CTGAGATGGCCGTTTCTCACAGAG-3’ (P1), intron 6 forward primer: 5’ATGCTCACTAGAGACCCAGTCCTC-3’ (P2), and

intron 6 reverse primer: 5’-

TTCACCAGGCTTTGGACACAGCAC-3’ (P3) and examined via gel electrophoresis.
When using the cassette specific primer sets, three bands are possible, WT - 210 bp (P2P3), Floxed - 250 bp (p2-p3 containing LoxP and BamH I sites), and CERK-KO - 528 bp
(P1-P3 without exon 6).
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Acute Wound Healing in Mice:
The acute wound closure rate was examined in mice as recently reported by us
(MacKnight et al. 2019). Specifically, a 5 mm biopsy punch was performed on the dorsum
of each mouse. Silicone stints were then place around the wound and a combination of
sutures and glue were used to hold said stints in place. Wounds were dressed using
Tegaderm (3M Medical) and imaged over the course of 10 days. Wound images were
analyzed using the Fiji image J bundle. Wounds were tracked as percent of initial wound
size over 10 days with or without CERK inhibition via small molecule inhibitor SYR382141
or genetic ablation (CERK-KO mouse). Treatment groups (n=5 mice/group) are:
Untreated, carboxymethyl cellulose (CMC) Sham Control (1% CMC), 60 mg/kg
SYR382141. The Sham and SYR382141 groups received an oral gavage twice a day for
9 days starting on day 1. Statistical analyses included Two-way ANOVA with Tukey posthoc. A significant difference was determined by a p < 0.05. At the end of ten days, tissues,
blood, and wounds were harvested.

Histology and Immunohistochemistry:
6 mm samples of wound tissue were excised after 10 days; wounds were prepared
for histological evaluation using the following procedure, as previously described by us
(Hill et al. 2019). Excised wounds were fixed by placing them in 4% paraformaldehyde for
24 hours, following fixation the wound was placed in a cassette that allowed for the
dehydration of the tissue, followed by clearing of the tissue using xylene (Fisher brand),
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and finally imbedding the tissue in paraffin wax. Sections (5 µm) of the paraffin block were
placed on clear glass slides for further treatment and staining. Staining with Masson’s
trichrome and hematoxylin & eosin was performed. Rabbit polyclonal anti-fibroblast
activation protein, alpha antibody (Abcam ab53066, 1:100) and rabbit polyclonal anti-type
I collagen (Abcam ab34710, 1:200) were used in immunohistochemical staining followed
by anti-Rabbit from Vectastain Elite kit (VectorLabs PK-6100) secondary and avidin-biotin
complex enhancement. All sections were visualized with Vector NovaRED Chromogen
kit (VectorLabs SK-4800) and counterstained with hematoxylin. Slides were viewed on
Keyence BZ-X710 microscope and analyzed using the Fiji image J bundle for watershed
cell counting or high contrast stained area calculation, where appropriate.

Isolation of Murine Dermal Fibroblasts:
Primary mouse dermal fibroblasts (pDFs) were isolated from 10-week-old WT,
CERK-KO, and cPLA2α-KI BALB/c males as previously described (Seluanov et al. 2010).
Once harvested, cells were cultured using high glucose Dulbecco's Modified Eagle
Medium

(DMEM)

(Gibco)

supplemented

with

20%

FBS

(Gibco) and

2%

penicillin/streptomycin (Bio Whittaker) at standard incubation conditions. Cells were not
used after passage 5.

Scratch-induced Mechanical Trauma of Fibroblasts:
pDFs obtained from WT, CERK-KO, and cPLA2α-KI mice were plated at a density
of 2 x 106 on 100 mm tissue culture plates in high glucose DMEM supplemented with 10%
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FBS (GIBCO) and 2% penicillin/streptomycin (Bio Whittaker) and left overnight to adhere
at standard incubation conditions. Following the overnight incubation cells were rested in
2% FBS (GIBCO) 2% penicillin/streptomycin (Bio Whittaker) high glucose DMEM (Gibco)
for 2 hours. After the 2-hour resting period mechanical trauma was induced on the
monolayer by performing scratches across the diameter of the plate in an asterisk pattern
using four 20 µl pipette tips on a multichannel micro pipettor. Media was taken for
lipidomic analysis at multiple time points (0 h and 2 h).

Exogenous Addition of CERK Inhibitors to HUVECs and HL-60 Cells:
HUVECs were plated at a density of 2 x 105 cells in a 6-well plate containing EGM2 Endothelial Cell Growth Medium-2 with BulletKit supplements (Lonza CC-3162) and
allowed to rest overnight. HL-60 cells were plated at a density of 1 x 106 cells in 100 mm
tissue culture plates containing Iscove′s Modified Dulbecco′s Medium (ThermoFisher
12200036) with 10% FBS (GIBCO). After the resting period, media was aspirated and
replaced with new growth media containing the addition of inhibitors (100 nM
SYR382141, 300 nM NVP-231, or 0.001% DMSO control) and allowed to rest for another
24hr before media and cell lysate collection for lipid analysis, as previously described by
us (Hoeferlin et al. 2015).

Analysis of Eicosanoids by UPLC ESI-MS/MS:
Eicosanoids were separated using a Shimadzu Nexara X2 LC-30AD coupled to a
SIL-30AC auto injector, coupled to a DGU-20A5R degassing unit in the following way as
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previously described by us (Hankins et al. 2013). A 14-minute reversed phase LC method
utilizing an Acentis Express C18 column (150mm x 2.1mm, 2.7μm) was used to separate
the eicosanoids at a 0.5 ml/min flow rate at 40°C as previously described by us (Hirano
et al. 2019; Mishra et al. 2019; Nelson et al. 2020) and others (Munagala et al. 2007; Van
Overloop et al. 2012). The column was equilibrated with 100% Solvent A
[acetonitrile:water:formic acid (20:80:0.02, v/v/v)] for 5 min and then 10 µl of sample was
injected. 100% Solvent A was used for the first two minutes of elution. Solvent B
[acetonitrile:isopropanol:formic acid (20:80:0.02, v/v/v)] was increased in a linear gradient
to 25% Solvent B at 3 min, to 30% at 6 min., to 55% at 6.1 min, to 70% at 10 min, and to
100% at 10.10 min. 100% Solvent B was held constant until 13.0 min, where it was
decreased to 0% Solvent B and 100% Solvent A from 13.0 min to 13.1 min. From 13.1
min to 14.0 min. Solvent A was held constant at 100%. Eicosanoids were analyzed via
mass spec using an AB Sciex Triple Quad 5500 Mass Spectrometer as previously
described by us (Mitra et al. 2007). Q1 and Q3 were set to detect distinctive precursor
and product ion pairs. Ions were fragmented in Q2 using N2 gas for collisionally induced
dissociation. Analysis used multiple-reaction monitoring in negative-ion mode.
Eicosanoids were monitored using precursor → product MRM pairs. The mass
spectrometer parameters as previously described by us (Chalfant et al. 2001; Wijesinghe
& Chalfant 2013) were: Curtain Gas: 20; CAD: Medium; Ion Spray Voltage: -4500V;
Temperature: 300°C; Gas 1: 40; Gas 2: 60; Declustering Potential, Collision Energy, and
Cell Exit Potential vary per transition.
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Migration Analysis of Fibroblasts:
Cells were seeded into 24 well tissue culture plates at a density of 7.5 x 10 4 and
allowed to grow to confluence. Once a confluent monolayer was achieved cells were
placed in 2% FBS (GIBCO)/2% penicillin/streptomycin (Bio Whittaker) high glucose
DMEM media and allowed to rest for 2-hours. After the 2-hour resting period, mechanical
trauma was induced on the monolayer by performing a single scratch across the diameter
of each well using a 20 µl pipette tip. Cells were observed using a live cell incubation
chamber mounted on a Keyence BZ-X710 microscope, which took images every 3 min
for 24hr. Migration Velocity was calculated using the Keyence VW-9000 motion analysis
software as previously described by us (MacKnight et al. 2019).

Exogenous Addition of Eicosanoids/inhibitors on Dermal Fibroblasts:
pDFs were seeded into 24 well tissue culture plates at a density of 7.5 x 10 4 and
allowed to grow to confluence. Once a confluent monolayer was achieved, cells were
placed in 2% FBS (Gibco) High Glucose DMEM media (Gibco) containing the addition of
various eicosanoids and/or inhibitors (Cayman Chemical) at the following concentrations:
1.0 nM 5-HETE (#34210), 1.0 nM 5-oxo-ETE (#34250), 7.5 nM MK886 (#21753), 10 µM
Gue1654 (#29686), 100 nM SYR382141, 100 nM NVP-231 (#13858)) and allowed to rest.
After the 2-hour resting period, mechanical trauma was applied as mentioned previously
and the media was exchanged with fresh 2% FBS (Gibco), high glucose DMEM media
(Gibco) containing the addition of various eicosanoids at the aforementioned
concentrations.
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Statistical Analysis:
Graphing and statistics were performed using Prism GraphPad (Prism Software,
San Diego, CA). Data were analyzed via ANOVA followed by Tukey’s post-hoc test or
Dunnett’s multiple comparisons test where applicable. All data reported as mean ±
standard deviation (SD); p < 0.05 was considered statistically significant.
Ethical Considerations:
All mouse studies were undertaken under the supervision and approval of the USF
IACUC (Protocol# IS00004094 and IS00004110) following standards set by the Federal
and State government. USF is fully accredited by AAALAC International as program
#000434.

Results
SYR382141 Inhibits Ceramide-1-Phosphate Production in Multiple Cell Types.
Previously, our laboratory reported that the interaction of ceramide-1-phosphate
(C1P) and group IVA phospholipase A2 was a negative regulator of acute wound healing
and the migration of dermal fibroblasts, but the source of C1P was not known. To examine
the source of C1P for these phenotypes, we obtained a new generation inhibitor of one
known source of mammalian C1P, ceramide kinase (CERK), which was developed by
Takeda corporation and designated SYR382141 and evaluated via previously described
analyses (Pettus et al. 2003; Slon-Usakiewicz et al. 2005; Wijesinghe et al. 2005; Van
Overloop et al 2006; Lamour & Chalfant 2008; Don & Rosen 2008; Graf et al. 2009; Wells
et al. 2021). This compound inhibited CERK activity in vitro with an IC50 of 5 nM for human
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CERK and 9 nM for mouse CERK. SYR382141 did not significantly affect the activity of
closely related kinases such as sphingosine kinase 1 and 2 (>100 µM, Table 2.1) as well
as kinases in a global kinase panel (1 µM; Table 2.1). SYR382141 also demonstrated an
IC50 of >30 μM to induce cytotoxicity in tissue culture (Table 2.1).

Table 2.1. SYR382141 compound in vitro and intracellular cytotoxicity studies.
Recombinant human and mouse ceramide kinase were assayed in the presence and
absence of various concentrations of SYR382141 using the ADP-Glo™ Kinase Assay
(Promega Corporation), The closely related lipid kinases, sphingosine kinase 1 and 2

Compound

SYR382141

Hm Enz IC50 (nM)

5

Ms Enz IC50 (nM)

9

SPHK1/SPHK2/PI4KB/PI3KC2A/PIK3C3
IC50 (μM)

>100

Global Kinase panel ≤ 1 μM
Cytotox 72h IC50 (μM)

Negative
30.3
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Table 2.1 (Continued): (SphK1, SphK2), phosphatidylinositol 4-kinase beta (PIK4B),
phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha (PI3KC2A), and
phosphatidylinositol 3-kinase catalytic subunit type 3 (PIK3C3), were also analyzed in the
presence and absence of various concentrations of SYR382141 also using the ADPGlo™ Kinase Assay (Promega Corporation). The effect of SYR382141 on a Global kinase
panel76 was also assessed. Lastly, cytotoxicity of SYR382141 was assessed in HepG2
cells via MTT assay as previously described (Goehe et al. 2010; Shultz et al. 2010; Vu et
al. 2016). Data are courtesy of Takeda Corporation.

To evaluate the ability of SYR382141 to inhibit CERK-derived C1P production in
cells, primary dermal fibroblasts (pDFs) and human umbilical vein endothelial cells
(HUVECs) were treated with SYR382141 or the positive control, the CERK inhibitor NVP231, and analyzed via ultraperformance liquid chromatography coupled with electrospray
ionization tandem mass spectrometry (UPLC-ESI-MS/MS)22,36 (Fig. 2.2). The levels of
detectable C1P species, D-e-C16:0 C1P (C16:0), D-e-C14:0 C1P (C14:0), D-e-C24:0 C1P
(C24:0), and D-e-C24:1 C1P (C24:1) were significantly reduced by SYR382141 in pDFs to
an equivalent or greater extent as NVP-231 (Pettus et al. 2003; Graf et al. 2008) using
nanomolar concentrations (Fig. 2.2A). Similar results were observed in HUVECs (Fig.
2.2B). Pharmacokinetically, SYR382141 treatment of mice demonstrated significant
plasma concentrations over 4 hours, which would allow for initial pre-clinical studies on
the effectiveness of inhibiting ceramide kinase in modulation of the in vivo phenotype,
acute wound healing (Table 2.2). These data demonstrate that nanomolar concentrations
of SYR382141 significantly blocks the production of CERK-derived C1P in cells
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analogous to an established inhibitor of the enzyme, but importantly, SYR382141 can be
utilized to inhibit CERK in mice.

Figure 2.2. SYR382141 decreases ceramide-1-phosphate levels in cells. (A) pDFs pretreated with SYR382141 (100 nM) or NVP-231 (100 nM) for 30 minutes received

40

Figure 2.2 (Continued): mechanical trauma via asterisk pattern scratch across the plate.
Cells were collected two hours post-injury and analyzed for C1P levels via UPLC ESIMS/MS. Values expressed as fold change to DMSO controls. (B) HUVECs were treated
with SYR382141 (100 nM) or NVP-231 (300 nM) for 24 hours. Cells were collected and
analyzed for C1P levels via UPLC ESI-MS/MS. Values expressed as fold change to
DMSO controls. (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; n=3. One-way ANOVA
with Tukey post-hoc test).

Table 2.2. Pharmacokinetics of SYR382141 in mice. The concentration of SYR38214
was analyzed in the plasma of mice retention in mouse plasma over the indicated time
using UPLC-ESI-MS/MS following oral gavage of the compound at the indicated
concentration. Data are courtesy of Takeda Corporation.

SYR382141 (15 mg/kg)
Mean Plasma
Mean Plasma
Time (hr)

Mean Plasma

Conc. (ng/mL)
Conc. (nM) Total Conc. (nM) Free
Total

0.5

5114

12247

73

1

4771

11426

69

4

586

1403

8

fu,plasma = 0.006
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CERK Inhibition and Genetic Ablation Improves Wound Closure Rate and Healing
Quality in vivo.
To determine whether CERK inhibitors could recapitulate the enhanced wound
healing observed in a genetically engineered mouse model where the C1P binding site in
cPLA2α was ablated (cPLA2α-KI mice; KI) (MacKnight et al. 2019), wild-type mice were
subjected to an acute excisional wound. One day post-wounding, wild-type mice were
treated twice daily, P.O. with the new generation ceramide kinase inhibitor, SYR382141,
versus the control (sham) and untreated mice. The dose of SYR382141 utilized showed
significant levels of the drug in mouse tissues (e.g., kidney) (Table 2.3), and importantly,
a significant increase in the rate of wound closure was observed after 10 days (Fig. 2.3).
CERK inhibition dramatically increased the presence of fibroblast activation protein (FAP)
and subsequent pDFs in the acute wounds at 10 days (Fig. 2.4). Furthermore, both the
Masson’s Trichrome stain and immunohistochemistry analysis for Type I collagen staining
indicate enhanced collagen Type 1 deposition. To confirm the specificity of the effect of
SYR382141 as via CERK inhibition, a novel CERK-KO mouse was examined in the same
context, but in the absence of SYR382141 treatment, which also showed a significant
increase in the rate of wound closure at days 6-10 (Fig. 2.3) as well as enhanced pDFs
(FAP staining) and collagen Type 1 in the wounds (Fig. 2.4). These data indicate that
C1P derived from CERK acts as a negative regulator of fibroblast migration into the
wound environment, and inhibition or genetic ablation of CERK significantly enhances
acute wound healing and maturation. Furthermore, inhibition of CERK is beneficial to
acute wound healing in a post-wounding manner.
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Table 2.3. Retention of SYR382141 in kidney. SYR382141 compound present in mouse
kidney tissue after 10 days PO b.i.d.
Untreated
SYR382141
conc.
Kidney (ng/g)

0.000

Sham
SD

± 0.000

SYR382141
conc.
0.000

60 mg/kg
SD

± 0.000

SYR382141
conc.
38.780

SD
± 12.968

Figure 2.3. Inhibition of ceramide kinase increases the closure rate of acute wounds in
mice. (A) Wound closure rate of 5mm biopsy wound on dorsum of CERK-KO or WT mice
± SYR382141, P.O. twice daily beginning one day post-injury (CMC Control, CERK-KO,
60 mg/kg SYR382141). (B) Acute wound closure rate quantified as percent of initial
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Figure 2.3 (Continued): wound size over 10 days (*p < 0.05 **p < 0.01 ***p < 0.001 ****p
< 0.0001; n=5. Two-way ANOVA with Šídák's multiple comparisons test).

Figure 2.4. Inhibition and genetic ablation of ceramide kinase improved wound quality.
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Figure 2.4 (Continued): (A) Wound tissue harvested 10 days post-injury from CMC WT
control, CERK knockout, and SYR382141-treated (60 mg/kg) WT mice under H&E (cell
infiltration), Masson’s Trichrome (collagen deposition), FAP (Fibroblast activation
protein), and Type I Collagen staining. (B) Quantification of infiltrating cells, FAP density,
and type I collagen density, analyzed via ImageJ cell counter and Fiji ImageJ bundle,
contrast enhanced (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; n=3. Two-way
ANOVA with Dunnett’s multiple comparisons test).

CERK Inhibition Enhances Dermal Fibroblast Migration.
To examine specific mechanisms that may contribute to an improved wound
healing rate, primary dermal fibroblasts (pDFs) were cultured ex vivo from WT and
homozygous CERK knockout (CERK-/-; CERK-KO) mice along with a positive control,
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pDFs cultured from homozygous cPLA2α knockin mice with the C1P interaction site
ablated (cPLA2α KI) (MacKnight et al. 2019). As previously reported, cPLA2α-KI
fibroblasts migrated more rapidly than WT (Fig. 2.5A&B). The same increase in migration
velocity was also observed for WT pDFs with inhibition of CERK using SYR382141 or the
CERK inhibitor, NVP-231, versus sham controls (Fig. 2.5A&B). Additionally, pDFs from
mice with CERK genetically ablated (CERK-KO), which produce a similar reduction in
C1P to SYR382141-treated pDFs (Fig. 2.5C), also showed a similar migration velocity
profile to that of SYR382141-treated WT and cPLA2α-KI fibroblasts (Fig. 2.5A&B). Also
of note, addition of SYR382141 or NVP-231 was unable to further enhance the migration
velocities of cPLA2α-KI or CERK-KO pDFs (Fig. 2.5B). Lipidomic analysis of SYR382141and NVP-231-treated WT pDFs as well as CERK KO pDFs after mechanical trauma
showed significant increases in multiple LOX-derived HETE species (e.g., 5-HETE, 12HETE, 15-HETE) as well as the more bioactive metabolite of 5-HETE, 5-oxo-ETE, and
the pro-inflammatory prostaglandin, PGE2, trended downward (Fig. 2.5D). Changes in 5HETE and 5-oxo-ETE production became evident as early as 60-minutes post-injury, but
no changes in the levels of the CERK substrate, ceramide, were observed (Fig. 2.6A&B).
Similar eicosanoid profiles were observed in HUVECs and HL-60 cells treated with NVP231 (Fig. 2.7). Lipidomic analysis of wound tissue from healed wounds in SYR382141treated mice displayed significant increases in 5-HETE and 5-oxo-ETE, but did not show
the reduced PGE2 levels observed in pDFs treated with CERK inhibitors (Fig. 2.8). These
data demonstrate that C1P derived from the anabolic enzyme, CERK, is a negative
regulator of 5-oxo-ETE biosynthesis and pDF migration via direct association with
cPLA2α.
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Figure 2.5. Inhibition or genetic ablation of ceramide kinase enhances the migration of
dermal fibroblasts and HETE biosynthesis. (A) Ex-vivo fibroblasts from WT, CERK-KO,
and cPLA2α-KI mice treated with DMSO (0.001%), SYR382141 (100 nM) or NVP-231
(100 nM). Still images from time points 0- and 24-hours. Brightness enhanced; lines
added for emphasis. Cells were observed using a live cell incubation chamber mounted
on a Keyence BZ-X710 microscope which took images every 3 min for 24hr. (B) Migration
velocities of pDFs treated with CERK inhibitors SYR382141 (100 nM) or NVP-231 (100
nM), calculated using the Keyence VW-9000 motion analysis software (Student’s t-tests;
n=4). (C) C1P (C:16 and C:24) production in wound tissue from CERK-KO mice
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Figure 2.5 (Continued): compared to WT. (D) Eicosanoids from WT, CERK-KO, and
cPLA2α-KI dermal fibroblasts pre-treated with SYR382141 or DMSO control collected 2
hours after mechanical injury (Two-way ANOVA with Dunnett’s multiple comparisons test;
*p < 0.05, **p < 0.01, ***p < 0.001, ***p < 0.001, ****p < 0.0001; n=3-4).

Figure 2.6. Scratch assay lipid changes over time. (A) Eicosanoid changes for wild-type
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Figure 2.6 (Continued): pDF scratch assay at times 0- and 60-minutes post-injury (n=3).
(B) Ceramide changes for wild-type pDF scratch assay at time 0- and 60-minutes postinjury (n=3). Wild-type pDFs were pre-treated with DMSO (0.01%) or NVP-231 (100 nM)
for 30 minutes received mechanical trauma via asterisk pattern scratch across the plate.
Cells were collected immediately (T=0) or 60-minutes (T=60) post-injury and analyzed for
eicosanoid and ceramide levels via UPLC ESI-MS/MS. Values expressed as fold change
to DMSO controls (*p < 0.05, ****p < 0.0001; n=3, pDFs collected from 3 different mice.
Two-way ANOVA with Šídák's multiple comparisons test).
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Figure 2.7. Eicosanoid profile of HUVEC and HL-60 cells. (A) Graphical analysis of
eicosanoids (n=6) and (B) C1P species (n=3) from HUVECs pre-treated with NVP-231
(300 nM) or DMSO (0.001%) control for 24 hours. (C) Graph depicting eicosanoid (n=3)
and (D) C1P species from HL-60 cells (n=3) treated with NVP-231 for 24 hours (Two-way
ANOVA with Šídák's multiple comparisons test; *p < 0.05, ****p < 0.0001).
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Figure 2.8. Inhibition of ceramide kinase enhances 5-HETE and 5-oxo-ETE biosynthesis
in acute wounds. (A) Heatmap representation of eicosanoid profile of wound tissue
harvested 10 days post-injury from WT mice treated with SYR382141 (60 mg/kg), or
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Figure 2.8 (Continued): Control (1% CMC) (n=3 per treatment group; one wound sample
per mouse). (B) Graphical comparison of C1P profile of wound tissue harvested 10 days
post-injury (n=3 per treatment; one wound sample per mouse. Two-way ANOVA with
Šídák's multiple comparisons test). (C) Graph depicting eicosanoid profile of wound tissue
harvested 10 days post-injury. (*p < 0.05, **p < 0.01, ***p<0.001, ****p<0.0001; n=3 per
treatment group; one wound sample per mouse. Two-way ANOVA with Šídák's multiple
comparisons test).

Enhanced Dermal Fibroblast Migration Requires 5-HETE/5-oxo-ETE Signaling via
an OXER1-like Receptor.
To determine whether the 5-HETE/5-oxo-ETE derived via the 5-Lipoxygenase/ 5Lipoxygenase-activating

protein

(FLAP)

pathway

drives

pDF

migration

in

a

paracrine/autocrine manner, we employed the FLAP inhibitor MK886 to prevent 5HETE/5-oxo-ETE production and Gue1654, a non-Gαi–biased antagonist of human
OXER1, which blocks 5-oxo-ETE–triggered functional events (Konya et al. 2014). MK886
and Gue1654 effectively reduced cPLA2α KI and CERK-KO pDF migration velocity to that
of WT pDFs, and blocked SYR382141 effects on the WT pDFs (Fig. 2.9). A combination
of MK886 and Gue1654 did not act additively or synergistically to block the effect of the
genetic ablation of the C1P/cPLA2α interaction or CERK inhibition. These data
demonstrate that 5-HETE/5-oxo-ETE drive the enhanced migration in cPLA2α KI and
SYR382141-treated or CERK-ablated pDFs via autocrine/paracrine signaling through a
murine G-protein coupled OXER1.
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Figure 2.9. MK886 and Gue1654 effectively reduce cPLA2α KI and CERK-KO pDF
migration velocity. (A) Graph depicting pDF migration velocity of WT, CERK-KO, and
cPLA2α-KI pDFs treated with combinations of FLAP inhibitor MK886 (7.5 nM), OXER1
antagonist Gue1654 (10 µM), ceramide kinase inhibitor SYR382141 (100 nM). All values
compared to WT DMSO control (n=3 per treatment; pDFs taken from 3 separate mice per
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Figure 2.9. (Continued): genotype. Two-way ANOVA with Dunnett's multiple comparisons
test; *p < 0.05, **p<0.01, ***p<0.001, ****p < 0.0001). (B) Graph depicting pDF migration
velocity of WT, CERK-KO, and cPLA2α-KI pDFs treated with combinations of 5-HETE
(100 nM), and 5-oxo-ETE (1 nM) treatments in combination with MK886 (7.5 nM) and
Gue1654 (10 µM). All values compared to panel (A) WT DMSO control (n=3 per
treatment; pDFs taken from 3 separate mice per genotype. Two-way ANOVA with
Dunnett's multiple comparisons test; *p < 0.05, **p<0.01, ***p<0.001, ****p < 0.0001). (C)
Representative microscope images of 5-oxo-ETE rescue and Gue1654 suppression of
pDF migration from data graphed in panels A and B. Contrast enhanced, lines added for
emphasis.

Discussion
In this study, we characterized both a new CERK knockout mouse and a new small
molecule inhibitor of CERK in the context of an enhanced wound healing phenotype.
Specifically, we showed that inhibition of CERK-derived C1P could recapitulate the finding
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that genetic ablation of the C1P/cPLA2α interaction site enhances acute wound healing
through increased dermal fibroblast migration and accelerated Type I collagen deposition
characteristic of non-fibrotic healed wounds (Wijesinghe et al. 2014). In this regard,
ceramide kinase ablation or inhibition with this novel compound did recapitulate enhanced
acute wound healing, and importantly, this effect occurred post-wounding, and thus, sets
the foundational pre-clinical studies to move forward for future clinical efficacy studies.
Furthermore, this study determines the source of C1P activating cPLA 2α signaling in
suppressing dermal fibroblast migration and wound maturation as ceramide kinase
versus another means of C1P biosynthesis like the reported mammalian S1P acylase
activity (Bionda et al. 2004).
This study also expanded the mechanistic knowledge as to how the association of
CERK-derived C1P with cPLA2α drives enhanced wound healing, wound maturation, and
pDF migration/collagen deposition. More specifically, this study demonstrated that CERKderived C1P negatively regulates 5-HETE biosynthesis with 5-HETE, but also showed
that 5-HETE was metabolized to 5-oxo-ETE, which is 100-fold more biologically active.
This 5-HETE metabolite was found to act in an autocrine/paracrine manner by activating
a murine OXER1 receptor to enhance pDF migration (Fig. 2.10). The murine OXER1
receptor has yet to be defined unlike the homologue to the human OXER1 receptor.
Regardless, the effectiveness of the OXER1 antagonist, Gue1654, which blocks both 5HETE and 5-oxo-ETE effects on pDF migration, shows the existence of an undefined
homologue of the human OXER1. A recent report by Lai et al. (2021) also demonstrates
that the uncharacterized murine OXER1 receptor does exist in mice due to successful
treatment with Gue1654 affecting coronary artery ligation-induced ischemic myocardial
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injury. Homology analysis shows that the mouse hydroxycarboxylic acid receptor 2
(HCAR2), which has been proposed to mediate 5-oxo-ETE responses in mice (Cooke et
al. 2013) and shares approximately 42% homology with human OXER1, is highly
expressed in adipose tissue and macrophages, and is expressed 3- to 5-fold higher when
exposed to inflammatory mediators (e.g., LPS, TNFα, IL-1) (Feingold et al. 2014).

Figure 2.10. Inhibition of CERK-induced C1P elevates 5-HETE and conversion to 5-oxoETE and subsequent action on OXER1-like receptor resulting in increased fibroblast
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Figure 2.10 (Continued): activity and expedited wound healing. The presence of CERK
results in elevated C1P, leading to an eicosanoid shift from HETEs to PGE2 resulting in
delayed wound healing via reduced fibroblast migration.

Future studies need to confirm this murine receptor as the target for Gue1654 in
mice to block 5-HETE and 5-oxo-ETE biological responses. Preliminary studies from our
group utilizing compounds reported to non-specifically down-regulate murine HCAR2 in
pDFs show similar migration inhibition effects as Gue1654 supporting the hypothesis that
HCAR2 is the 5-oxo-ETE receptor in mice. Overall, this study can conclude that an
OXER1 G-protein coupled receptor exists in mice, which is required for 5-HETE and 5oxo-ETE to enhance pDF migration, but this study cannot confirm the exact receptor
homologue to human OXER1 at this time.
Notably, both the loss of C1P/cPLA2α interaction and the inhibition of CERK
resulted in dramatic decrease of inflammatory prostaglandins concomitant with 5-HETE
increase. Indeed, C1P reportedly increases during the inflammatory stage of wound
healing in human subjects, but then decreases during the proliferation and remodeling
stages (Wijesinghe et a. 2014). These findings, when coupled with C1P being a negative
regulator of proliferation and wound maturation (MacKnight et al. 2019), suggest that C1P
is a pro-inflammatory mediator modulating the inflammatory stage and an essential “stopgap” in the subsequent activation of the proliferation stage. Thus, blocking C1P
production or C1P interaction with cPLA2α proves to be beneficial for condensing the
inflammatory phase and inducing the proliferation/remodeling phases earlier by
enhancing fibroblast activity. Interestingly, CERK inhibitors also increased other pro57

resolution 15-LOX-derived eicosanoids such as 15-HETE and RVD1 in various cell types.
These data further suggest that C1P may regulate additional PLA 2 isoforms, which
regulate the production of these specific eicosanoids. One possibility could be cPLA 2β,
which has not been well characterized and contains a C2-domain analogous to cPLA2α
(Ohto et al. 2005; Ghomashchi et al. 2015).
One conundrum from our study is the observation that inhibition of C1P improves
pDF migration. Although congruent with our previous finding in mouse embryonic
fibroblasts with CERK ablated, other laboratories have reported that C1P treatment
induces cellular migration in macrophages (Granado et al. 2009) and pancreatic cells
(River et al. 2016). We hypothesize that these differences may be due to the cellular
localization of C1P. For instance, exogenous C1P treatment using a vesicle-based
delivery mainly increases the C1P content of the plasma membrane (PM) in various cell
types (Katz et al. 2016) with rapid metabolism to ceramide observed (Mitra et al. 2007).
This PM pool of C1P may encourage migration via association with factors such as
annexins (Hankins et al. 2013). Additionally, the reported opposing functions of C1P on
cell migration may be due to cell type-specific variances as in our studies. Indeed, our
studies utilize fibroblasts, whereas other reports show that C1P enhances macrophage
migration (Granado et al. 2009). Inhibition of C1P may reduce macrophage-induced
inflammation in the wound, which is a plausible mechanism to accelerate dermal wound
healing. Our current study argues against a cell type-specific variance as we show that
both HUVECs and HL-60s increase 5-HETE and 5-oxo-ETE in response to CERK
inhibition, and thus, any context variations are likely due differences in OXER1 activation
in s specific cell types.
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Metabolism to other sphingolipids that drive cellular migration may also be a
plausible explanation for the differential reports on C1P in cell migration (e.g., catabolism
to sphingosine-1-phosphate) (Mishra et al. 2020). Furthermore, an additional anabolic
pathway for C1P generation does exist in mammalian cells, which may involve an S1Pacylase (Binoda et al. 2004) at the PM. CERK-derived C1P is more recognized as a Golgiform of C1P (Lamour et al. 2007) and associated with cPLA2α activation and eicosanoid
biosynthesis. The form of C1P may inhibit migration due to association with cPLA2α
localized to this organelle and modulation of specific eicosanoids (e.g., PGE 2) (Schultz et
al. 2011). Additionally, transport of C1P to the PM by CPTP remains a plausible regulatory
mechanism between Golgi-C1P blocking migration and PM-C1P enhancing migration, or
by limiting C1P release for paracrine effects (Simanshu et al. 2013; Mishra et al. 2018).
CERK regulation and C1P anabolism are still an enigma in the field, which was mainly
due to a lack of sensitive techniques to consistently measure C1P levels accurately in
cells. Although this issue is now rectified, C1P biosynthesis has not been strongly
revisited. Originally, due to the very low levels of C1P in the cells versus the substrate of
CERK, ceramide, conversion to C1P was not considered a plausible cellular “rheostat”
for reducing ceramide levels to block pro-apoptotic mechanisms. The discovery of the
C1P transport protein (CPTP) in 2013 dispelled that dogma as these studies found a high
level of “flux” of ceramide through CERK in some cell types, which was rapidly transported
from the Golgi to other cellular organelles and catabolized (Simanshu et al. 2013). In this
study, no increases in ceramides in the time frame (60 minutes) that C1P increases by
~2-fold was observed. Inhibition of CERK caused a marked trend in the increase of
ceramide levels after mechanical trauma to cells in culture, but these differences were
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not significant suggesting either CERK activation or CPTP inhibition/downregulation is
the mechanism of C1P induction. Nonetheless, the unique functions for specific C1P
anabolic pathways require further study to elucidate their specific cellular roles, which
may be opposing depending on the topology of the C1P production or cell type specific.
With recent advances in examining metabolic “flux” of sphingolipids via mass
spectrometry, the regulatory mechanisms for C1P biosynthesis can be explored in the
future in detail.
One of the more important outcomes of this study is the demonstration of rapid
acute wound closure from C1P inhibition in vivo in a post-wounding manner. Thus, topical
treatment of wound with a CERK inhibitor could be effective in enhancing wound healing
and possibly even incorporated into antibiotic ointments in future studies. One of the
unique strengths of SYR382141 is its ability to significantly reduce C1P levels in vivo.
Additionally, CERK inhibiting drugs may also be adaptable to chronic wounds, which fail
to resolve and are “stalled” in the inflammatory stage possibly due to continued C1P
production, high PGE2 (Parekh et al. 2009), and elevated neutrophil activity (Kim et al.
2008). Indeed, the main component of the venom of the Brown Recluse spider (Truett &
King 1993) is sphingomyelinase D (SMase D), which hydrolyzes sphingomyelin to C1P.
The dermal necrosis/ulceration induced by SMase D is well-documented in patients bitten
by the Brown Recluse spider (Rees et al. 1984), which presents as ulcerative wound
similar in many aspects to a pressure ulcer. Thus, the chronic synthesis of C1P would be
a plausible driver of “stalled” wound healing. CERK inhibitors may have the ability to
suppress the synthesis of C1P as well as PGE2 (Pettus et al. 2005), enhance 5-HETE
and 5-oxo-ETE production, and induce fibroblast activation, thus promoting wound
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healing of stall wounds linked to neutrophilia and a chronic inflammatory stage. On the
other hand, some pathogenic bacteria also have SMase D (Mariutti et al. 2017; Cockburn
et al. 2019), which may stall wound healing independent of CERK, and thus, a
combination therapy of 5-oxo-ETE and CERK inhibitors may provide more benefit in a
clinical setting where the wound microbiome is also a major factor in wound healing
outcomes. Lastly, a better mechanistic understanding of the CERK/5-oxo-ETE interplay
could be valuable for treating other diseases highly correlated to these lipid biomarkers
such as preeclampsia (Walsh et al. 2020; Amraoui et al. 2020) and type 1 diabetes
(Priyadarsini et al. 2016; Nelson et al. 2020).
In conclusion, this study demonstrates that enhanced wound healing and
maturation is induced by blocking CERK-derived C1P, which is a negative regulator of
fibroblast function and the 5-HETE/5-oxo-ETE/OXER1 axis.

Our findings show the

importance of sphingolipids and resulting eicosanoids in the wound healing process and
provide the groundwork for foundational pre-clinical studies to move forward for future
clinical therapeutic development of CERK inhibiting drugs that accelerate the healing rate
and closure of wounds, especially for post-injury treatment.

Reprinted from Journal of Lipid Research, 100187, Maus, K. D., Stephenson, D. J., Ali,
A. N., MacKnight, H. P., Huang, H-J., Serrats, J., Kim, M., Diegelmann, R. F., Chalfant,
C. E. Ceramide kinase regulates acute wound healing by suppressing 5-oxo-ETE
biosynthesis and signaling via its receptor OXER1, (2022), with permission from Elsevier.
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Limitations
One limitation of this study is the pure novelty of SYR382141.Because SYR382141
is a first generation compound with a proprietary formulation, not much is known about
its specific mechanism of action, stability, or potential for refinement. We attempted to
offset this unknown by utilizing the CERK-KO mouse model as a control, but we
acknowledge that both of these experimental models are difficult for most labs to
replicate. Additionally, there exists some noncanonical pathway for C1P generation, as
even the genetic ablation of CERK resulted in reduction of only 40-60% C1P levels
compared to WT cells. Indeed, this is also evident in siRNA knockdown of CERK in
HUVEC cells (data not shown). Because of this, we were careful to use the phrase
“CERK-derived C1P” when discussing our results and data, but this limitation remains.
Lastly, our animal work was conducted in GEMMS of a C57BL/6 background, and it’s
known that mice of different genetic backgrounds can display varying wound healing
phenotypes. However, we carefully considered the C57BL/6 background to remain
consistent with the majority of murine wound healing studies present in the literature in
an attempt to minimize this variable.
Note to Reader: Portions of this chapter have been accepted for publication in Journal
of Lipid Research, 2022, 100187, and have been reproduced with permission under a
Creative Commons license. Author Contributions: KDM (first author)- designing
research studies, conducting experiments, acquiring data, analyzing data, and writing the
manuscript. DJS, ANA, HPM, H-JH, JS, MK, RFD - designing research studies,
conducting experiments, acquiring data, analyzing data. CEC - designing research
studies, analyzing data providing reagents, and writing the manuscript.
62

CHAPTER THREE: CERAMIDE-1-PHOSPHATE/CPLA2α INTERACTION
REGULATES NEUTROPHIL POLARIZATION AND FUNCTION IN MAMMALIAN
INFLAMMATORY RESPONSES.

Abstract
Ablating the C1P interaction site on Group IVA cytosolic phospholipase A2
(cPLA2α) results in enhanced wound healing and increased levels of the specific
hydroxyeicosatetraenoic acid species 5-HETE and its downstream metabolite 5-oxoETE. The studies in this chapter demonstrate enhanced neutrophil infiltration during the
inflammatory phase of both acute wound healing and sepsis in mice that express cPLA 2α
with an ablated C1P interaction site (cPLA2α-KI) versus wild-type (WT) and cPLA2α
knockout (cPLA2α-KO) mice. This enhanced neutrophil infiltration correlated with
significant improvement of acute and chronic wound healing as well as a significant
increase in the survival of mice subjected to sepsis via cecal-ligation and puncture or fecal
injection. Since neutrophilia normally correlates with poor healing and survival outcomes
in mouse models and human patients, the neutrophil subtype was characterized. In this
regard, cPLA2α-KI neutrophils showed significantly enhanced phagocytosis and VEGF
production along with decreased levels of TNFα, neutrophil extracellular trap (NET)
production, and damage to the endothelial layer versus WT and cPLA 2α-KO neutrophils,
which is analogous to a less inflammatory, N2-phenotype. Inhibition of the pentose
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phosphate pathway (PPP) or treatment with 5-HETE/5-oxo-ETE in WT neutrophils
recapitulated specific aspects of the N2 phenotype of pro-phagocytotic/anti-inflammatory
behavior. Together, these studies demonstrate the C1P/cPLA2α interaction as a key
negative regulator of 5-oxo-ETE biosynthesis in controlling neutrophil polarization via
modulation of the PPP. Additionally, these findings suggest plausible therapeutic targets
to effectively enhance chronic wound healing and increase the survival of sepsis patients.

Introduction
A hallmark of healthy wound progression is the transition from inflammatory phase
to proliferation and ultimately tissue remodeling. The inflammatory stage recruits
circulating neutrophils into damaged tissues to rapidly eliminate pathogens and external
debris from the wound site (Nathan 2006). Neutrophil infiltration initiates inflammation,
and their timely clearance by macrophages, known as efferocytosis, is crucial for proper
progression into subsequent phases of wound healing (Fig. 3.1). The physiologic
condition of sepsis is also initially characterized by a hyperinflammatory stage as shown
by the presence of fever, tachycardia, tachypnea, and altered leukocyte numbers along
with a known site of infection (Dal-Pizzol et al. 2021). As with wound healing, neutrophil
infiltration, in this case into the peritoneum, is also required to clear pathogen,
macrophages, damaged tissue, and efferocytosis to drive eventual resolution and
recovery. However, both wounds and the septic response can become stalled in the
inflammatory stage, causing delayed healing or resolution as well as hyperinflammation
as inflammatory cytokines (e.g., TNFα) are overproduced (Patel et al. 2016; Zhang et al.
2016). Because neutrophils rely on many pro-inflammatory mechanisms to combat
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pathogens, the specific behaviors of neutrophils in a wound site and peritoneum are of
great importance. Indeed, a prolonged increase in circulating neutrophils, known as
neutrophilia, is strongly linked to poor outcomes in both wound healing and sepsis (Dovi
et al. 2004; Hoesel et al. 2005).
Previous findings from our lab suggested the potential for additional stages of
wound healing to be compressed (MacKnight et al. 2019). Previous research suggests
that suppression of neutrophilia and neutrophil infiltration is generally a hallmark of better
healing outcomes (Kolaczkowska & Kubes 2013). Thus, we examined whether neutrophil
infiltration was suppressed in our GEMM.

Figure 3.1. Wound healing is an evolutionarily conserved process consisting of four
distinct yet overlapping phases: hemostasis, inflammation, proliferation, and remodeling.
Infiltration of neutrophils marks the beginning of inflammation and their timely exit often
65

Figure 3.1 (Continued): coincides with the onset of proliferation. Compression of the
inflammatory phase often confers rapid wound healing and prevents wounds from
“stalling” and becoming chronic.

As one of the most abundant cells of the immune system, neutrophils are
extremely active during the repair of cutaneous wounds (Burn et al. 2021). Neutrophils
use a combination of microbial engulfment and secretion of anti-microbials to kill invading
pathogens (Guimaraes-Costa et al. 2012). In addition to sterilizing the wound, these
secreted components can also cause significant tissue damage to the host (Kruger et al.
2015), leading to delayed healing and excessive scar formation (Wilgus et al. 2013). Much
of this host damage results from the activity of reactive oxygen species (ROS) secreted
by neutrophils during inflammatory response (Soehnlein et al. 2017). In addition to ROS,
neutrophils secrete chromatin “traps” termed neutrophil extracellular traps (NETs)
comprised of chromosomal DNA and globular proteins to ensnare extracellular invaders
and deliver a concentrated dose of antimicrobial components (Brinkmann et al. 2004).
However, evidence suggests that NETs can also participate in the pathogenesis of
autoimmune and inflammatory disorders (Cooper et al. 2013) and occlude the
vasculature, causing delayed wound healing (Wong et al. 2015; Meegan et al. 2017).
Neutrophil polarization is a relatively young field first characterized by Fridlender
et al. in 2009 that explores a class-switch in neutrophil behavior between a proinflammatory, cytotoxic phenotype, dubbed N1, and an anti-inflammatory, pro-resolution
phenotype, dubbed N2. These distinct neutrophil populations are typically determined by
their functional phenotype (Coffelt et al. 2016), but specific cell surface receptors ICAM66

1 and CXCL10 for N1 and IL-8 and CXCR2 for N2 are now generally accepted markers
in the research community (Ohms et al. 2020). While the concept of macrophage
polarization between “resting” and “activated” macrophages has long been linked to
glycolytic flux (Jha et al. 2015), neutrophils were presumed to be metabolically inert due
to their transient appearance during infection and relatively short lifespan. However,
oxidative metabolism is an essential component of the characteristic ‘respiratory burst’
and production of reactive oxygen species (ROS) and extracellular traps (NETs) used by
neutrophils to kill microbial invaders (Phelan & Sheedy 2021). The oxidative pentose
phosphate pathway (PPP) is a common source of reducing power in various intracellular
processes of the immune response (Ghergurovich et al. 2020). Indeed, a recent study
showed that activated human neutrophils shunted metabolic activity away from pyruvategenerating glycolysis in favor of the PPP, thereby enhancing the antimicrobial function of
the neutrophils (Amara et al. 2021). Additionally, the PPP enzymes glucose-6-phosphate
dehydrogenase (G6PD) and 6-phosphogluconate dehydrogenase (PGD) produce
NADPH to fuel superoxide production via NADPH oxidase during NET formation
(Azevedo et al. 2015). Thus, the PPP is a prominent target in elucidating neutrophil
polarization in the wound healing process.
In this chapter, contrasting phenotypes were unexpectedly observed in mouse
models of sepsis and wound healing. Neutrophilia was detected in acute wounds and in
the peritoneum following sepsis induction in cPLA2α-KI mice, but surprisingly the overall
outcome for survival and wound healing was positive. An increase in the trans-endothelial
migration of neutrophils could be recapitulated in vitro, which required a distinct lipid
“fingerprint” marked by the induction of 5-HETE and its downstream metabolite, 5-oxo-
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ETE. Due to these seemingly contradictory outcomes, this study further evaluates the
polarity and cellular behaviors of cPLA2α-KI neutrophils. The experimental findings in this
chapter point toward cell pathways involved in regulating neutrophil polarization to the N2
phenotype. Namely, increased 5-HETE biosynthesis, 5-oxo-ETE metabolism and
activation of the OXER1 receptor, and PPP modulation. Overall, these data reinforce the
integral role that eicosanoids play in both the wound healing process and sepsis
resolution by demonstrating a novel role for 5-HETE/5-oxo-ETE in neutrophil polarization
and suggest eicosanoid-driven adjustment of the pentose phosphate pathway, providing
new potential targets for therapeutic approaches to treating hyperinflammatory wounds
and sepsis.

Materials and Methods
PCR-based Identification of WT, cPLA2α-KI, and cPLA2α-KO:
Genotyping of WT, cPLA2α-KI, and cPLA2α-KO mice was performed by first
collecting genomic DNA using an Accustart II genotyping kit followed by polymerase chain
reaction (PCR) as previously described by us (Paronetto et al. 2007; Gowda et al. 2021)
using the following primers: KO: PLA2 58534-58556 (P1), PLA2 58780-58757 (P2), and
KI: PLA2 58534-58556 (P1), PLA2 58780-58757 (P2), and SV40 2590-2567 (P3). 50ng of
genomic DNA was used for each reaction at the following reaction cycles repeated 33
times, 94°C for 1 min, 59°C for 1 min, and 72°C for 2 min. Reaction products expected
are as follows cPLA2α-WT: 237bp, cPLA2α-KI: 412bp, and cPLA2α-KO: 361bp and were
examined using a 2% agarose gel.
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Cecal Ligation and Puncture (CLP) Surgical Procedure:
Male mice (6-12 weeks of age) were anesthetized with isoflurane @ 5% for
induction and @ 3% for surgical procedures. A longitudinal midline incision was made
with a scalpel, being careful not to penetrate into the peritoneal cavity. After the initial
incision, entry into the peritoneal cavity (mice, 1.5–2 cm; rats, 3–4 cm;) was completed to
gain access to the cecum. The cecum was ligated with 2.0 silk ties at the designated
position for the desired severity grade (High-grade/Severe ~75% ligation). The cecum
was perforated with a 26-gauge needle by single through-and-through puncture midway
between the ligation and the tip of the cecum in a mesenteric-to-antimesenteric direction.
After removing the needle, extrude a small amount (droplet) of feces from both the
mesenteric and antimesenteric penetration holes. Peritoneum and abdominal
musculature were closed by applying simple running sutures. Mice were injected with
prewarmed normal saline (37 °C; 5 ml per 100 g body weight) subcutaneously and
monitored every 30 minutes for 3 hours. Post- surgical recovery monitoring occurred
every 6-12 hours for 7- days.

Acute Wound Healing in Mice:
The acute wound closure rate was examined in mice as recently reported by us
(MacKnight et al. 2019). Specifically, a 5 mm biopsy punch was performed on the dorsum
of each mouse. Wounds were dressed using Tegaderm (3M Medical) and imaged over
the course of 72 hours using an in vivo imaging system (IVIS). Wound images were
analyzed using the Living Image software (Perkin Elmer) and GFP fluorescence (RFUs)
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of regions of interest (ROI) were measured with excitation wavelength of 480 nm and
emission wavelength of 550 nm. Wounds were tracked as percent of RFUs over 72 hours
WT or cPLA2α-KI mice (n=5 mice/group, repeated on two separate occasions). Statistical
analyses included Two-way ANOVA with Tukey post-hoc. A significant difference was
determined by a p < 0.05.

Western Blotting:
Total cellular protein (5-10 µg) was electrophoretically separated on 10% SDSpolyacrylamide gels. Samples were electrophoretically transferred to PVDF membranes,
blocked with non-fat milk, and probed with the indicated antibodies for proteins of interest.
Antibodies were purchased from ThermoFisher (G6PD polyclonal, cat no. PA5-27359,
1:1000; PGD polyclonal, cat no. PA5-83188, 1:1000; TMX polyclonal, cat no. PA5116605, 1:1000).

Cell Culture and Reagents:
Human umbilical vein endothelial cells (HUVECs) (Lonza C2519A) were cultured
in EBM-2 endothelial cell growth basal media (Lonza CC-3156) and SingleQuots™
supplement kit (Lonza CC-4176). Cells were maintained in a 95% air / 5% CO2 incubator
at 37 °C. Cells were passaged every 3-5 days at > 90% confluency, and all experiments
were performed within 8 passages.
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Exogenous Addition of Small Molecule Inhibitors to Neutrophils:
Eicosanoids and/or inhibitors (Cayman Chemical) were applied at the following
concentrations: 1.0 nM 5-HETE (#34210), 1.0 nM 5-oxo-ETE (#34250), 7.5 nM MK886
(#21753), 10 µM Gue1654 (#29686), 100 nM Physcion (Santa Cruz Biotech SC-205805).
Cells were allowed to equilibrate with inhibitors for 30 minutes before experimentation.

ELISA Assays for Cytokines, Phagocytosis, ROS Production, Cell Surface Markers, and
NETosis:
ELISA assays were performed as instructed by manufacturer. Kits used were as
follows: G6PD activity assay kit (Abcam #ab176722), PGD activity assay kit (Abcam
#ab273328), NETosis assay kit (Cayman #601010), ROS detection assay kit (Cayman
#601290), mouse VEGF kit (Fisher #MMV00), mouse TNFα kit (Fisher #MTA00B),
Phagocytosis assay kit (Cell Biolabs #CBA-222), Mouse Syndecan-1 ELISA kit (Abcam
#ab273165), ICAM-1 ELISA kit (R&D Systems #MIC100), CXCL10 ELISA kit (R&D
Systems #DY466-05), IL-8 ELISA kit (MyBioSource #MBS7606860), CXCR2 ELISA kit
(MyBioSource #MBS726530).

Neutrophil trans-endothelial Migration Assay (NTEM):
HUVECs were seeded on the upper wells Corning® Transwell® polycarbonate
membrane inserts with 3.0 µm pores (Sigma-Aldrich CLS3415) inserted into a 24-well
tissue culture plate at a density of 1.6 x 106 cells per ml in 250 µl volume. Inflammatory
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response was induced by adding TNFα (Cayman #32020, 20 ng/ml) 16-18 hours before
addition of PNs. PNs were then isolated from mouse bone marrow and added to the upper
well while HUVEC media containing lipopolysaccharides (LPS) from E. coli (Millipore
Sigma #L3023, 1 µg/ml) was added to the bottom well as a chemoattractant. After time
indicated (e.g., 6 hours), cells from the lower well were counted via hemocytometer to
determine how many neutrophils successfully migrated through the endothelial layer
toward the chemoattractant.

Analysis of Eicosanoids by UPLC ESI-MS/MS:
Eicosanoids were separated using a Shimadzu Nexara X2 LC-30AD coupled to a
SIL-30AC auto injector, coupled to a DGU-20A5R degassing unit in the following way as
previously described by us (Hankins et al. 2013). A 14-minute reversed phase LC method
utilizing an Acentis Express C18 column (150mm x 2.1mm, 2.7μm) was used to separate
the eicosanoids at a 0.5 ml/min flow rate at 40°C as previously described by us (Hirano
et al. 2019; Mishra et al. 2019; Nelson et al. 2020) and others (Munagala et al. 2007; Van
Overloop et al. 2012). The column was equilibrated with 100% Solvent A
[acetonitrile:water:formic acid (20:80:0.02, v/v/v)] for 5 min and then 10 µl of sample was
injected. 100% Solvent A was used for the first two minutes of elution. Solvent B
[acetonitrile:isopropanol:formic acid (20:80:0.02, v/v/v)] was increased in a linear gradient
to 25% Solvent B at 3 min, to 30% at 6 min., to 55% at 6.1 min, to 70% at 10 min, and to
100% at 10.10 min. 100% Solvent B was held constant until 13.0 min, where it was
decreased to 0% Solvent B and 100% Solvent A from 13.0 min to 13.1 min. From 13.1
min to 14.0 min. Solvent A was held constant at 100%. Eicosanoids were analyzed via
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mass spec using an AB Sciex Triple Quad 5500 Mass Spectrometer as previously
described by us (Mitra et al. 2007). Q1 and Q3 were set to detect distinctive precursor
and product ion pairs. Ions were fragmented in Q2 using N2 gas for collisionally induced
dissociation. Analysis used multiple-reaction monitoring in negative-ion mode.
Eicosanoids were monitored using precursor → product MRM pairs. The mass
spectrometer parameters as previously described by us (Chalfant et al. 2001; Wijesinghe
& Chalfant 2013) were: Curtain Gas: 20; CAD: Medium; Ion Spray Voltage: -4500V;
Temperature: 300°C; Gas 1: 40; Gas 2: 60; Declustering Potential, Collision Energy, and
Cell Exit Potential vary per transition.

Isolation of Murine Bone Marrow-Derived Neutrophils:
Mouse neutrophils were harvested from bone marrow as previously described
(Ubags & Suratt 2018). In brief, bone marrow was flushed using 1x Hank’s Balanced Salt
Solution (HBSS) (ThermoFisher #14185052), washed, and centrifuged at 1545 x g for 30
minutes over a Percoll™ gradient (Fisher #45001748) consisting of 72%, 64%, and 52%
solutions. After centrifugation, a pure, mature neutrophil population will be retained at the
72%-64% interface. Non-neutrophil layers are decanted and the neutrophil population is
washed in 1x (HBSS) and counted via hemocytometer. Neutrophils were used for
experimentation immediately after isolation and were not maintained or passaged in
media.
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Histology and Immunohistochemistry:
6 mm samples of wound tissue were excised at indicated time points (e.g., 0- and
6-hours post-injury); wounds were prepared for histological evaluation using the following
procedure, as previously described by us (Hill et al. 2019). Excised wounds were fixed by
placing them in 4% paraformaldehyde for 24 hours, following fixation the wound was
placed in a cassette that allowed for the dehydration of the tissue, followed by clearing of
the tissue using xylene (Fisher brand), and finally imbedding the tissue in paraffin wax.
Sections (5 µm) of the paraffin block were placed on clear glass slides for further
treatment and staining. Staining with Masson’s trichrome and hematoxylin & eosin was
performed. Rabbit monoclonal anti-Ly6g antibody (Abcam ab238132, 1:1000), rabbit
polyclonal anti-neutrophil elastase (Abcam ab68672, 1:200), rabbit monoclonal antiF4/80 (Abcam ab111101, 1:100), and rabbit polyclonal anti-CD86 (Abcam ab125212, 1
µg/ml) were used in immunohistochemical staining followed by anti-Rabbit from
Vectastain Elite kit (VectorLabs PK-6100) secondary and avidin-biotin complex
enhancement. All sections were visualized with Vector NovaRED Chromogen kit
(VectorLabs SK-4800) and counterstained with hematoxylin. Slides were viewed on
Keyence BZ-X710 microscope and analyzed using the Fiji image J bundle for watershed
cell counting or high contrast stained area calculation, where appropriate.

Statistical analysis:
Graphing and statistics were performed using Prism GraphPad (Prism Software,
San Diego, CA). Data were analyzed via ANOVA followed by Tukey’s post-hoc test or
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Dunnett’s multiple comparisons test where applicable. All data reported as mean ±
standard deviation (SD); p < 0.05 was considered statistically significant.

Ethical considerations:
All mouse studies were undertaken under the supervision and approval of the USF
IACUC (Protocol# IS00008261 and IS00008191) following standards set by the Federal
and State government. USF is fully accredited by AAALAC International as program
#000434.

Results
C1P-cPLA2α Ablation Enhances Neutrophil Infiltration Into Acute Wounds.
In vivo fluorescence imaging of WT and cPLA2α-KI mice with EGFP-labeled MLysderived cells following acute dermal wounding demonstrated significantly higher
neutrophil infiltration into KI wounds (Fig. 3.2A). Increased fluorescent cells were present
in the wound site as early as 4 hours post-injury and remained elevated for over 24 hours
(Fig. 3.2B). This increase in neutrophil infiltration was further examined using models of
sepsis, fecal injection and the cecal-ligation and puncture. As with acute wound healing,
neutrophil infiltration was increased, in this case in the peritoneum. KI mice demonstrated
a shift toward neutrophil-mediated inflammatory response at time points T=4 hours and
T=12 hours post-IP injection as opposed to macrophage-mediated inflammation
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observed in WT mice as indicated via flow cytometry (Fig. 3.3A). Survival against sepsis
induction via cecal ligation was also dramatically increased in KI mice versus WT and
cPLA2α-KO mice (Fig. 3.3B).

Figure 3.2. (A) Infiltrating fluorescent MLys-derived cells at times 0-, 2-, 4-, 6-, 12-, and
24-hours post injury. (B) Quantification of fluorescence as fold-change to t=0 (n=5 mice).
Data displayed as mean ± SD. Two-way ANOVA with Dunnett’s multiple comparisons
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Figure 3.2 (Continued): (**p<0.01, ***p<0.001, ****p<0.0001).

Figure 3.3. Neutrophilia and improved sepsis outcomes. (A) Sepsis data showing higher
neutrophil to macrophage ratio in sepsis model at T=4h and 12h (Two-way ANOVA with
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Figure 3.3 (Continued): Tukey’s post-hoc test; *p < 0.05, n=4-8). (B) Survival proportions
of CLP-model sepsis mice (Log-rank Mantel-Cox test, KI vs KO p = 0.0034, KI vs WT p =
0.0430, n=15-20).

To confirm the ratios of neutrophils to macrophages between genotypes, we
employed immunohistological staining for well-established cell-specific markers (Kunisch
et al. 2004; Anabzada et al. 2011; Yu et al. 2015; Zhou et al. 2020). These data
demonstrated no significant differences between genotypes at time of injury, but by the
6-hour mark, cPLA2α-KI mice showed a higher presence of neutrophils in the wound
tissues compared to WT mice (Fig. 3.4). Specifically, neutrophil marker Ly6G was
increased approximately 10% in KI mice. Similarly, macrophage markers CD68 and F4/80
were increased approximately 15% in WT mice compared to cPLA 2α-KI (Fig. 3.4C),
indicating higher macrophage-mediated inflammatory response in WT mice.
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Figure 3.4. Neutrophil and macrophage histological markers in cPLA2α-KI and WT
wound tissue. Tissue section from to acute dorsal wounds of the cPLA2α WT and cPLA2α
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Figure 3.4 (Continued): KI mice from the indicated times (t=0 and t=6 hours post-injury)
were subjected to histological staining for neutrophils (Ly6G, Neutrophil elastase) and
macrophages (CD68, F5/80) for the indicated times (t=0 and t=6 hours post-injury).
Neutrophils and macrophages were quantified by stained area as fold-change to WT
tissue. Each time point is n = 10 wounds (5 mice), which was repeated on two separate
occasions. Data displayed are mean ± SD. Statistical analysis was done via two-way
ANOVA with Dunnett’s multiple comparisons; **p<0.01, ***p<0.001.

C1P-cPLA2α Ablation Enhances Neutrophil Infiltration via 5-oxo-ETE Through an
OXER1-like Receptor.
cPLA2α-KI neutrophils display a nearly 4-fold increase in NTEM over WT and
cPLA2α-KO neutrophils after 4 hours incubation (Fig. 3.5A). cPLA2α-KI Neutrophils
possessed a lipidomic profile of elevated 5-HETE and 5-oxo-ETE compared to WT and
cPLA2α-KO cells, while cPLA2α-KI and cPLA2α-KO had decreased PGE2 compared to
WT cells (Fig. 3.5B&C). Inhibiting 5-HETE production via FLAP inhibitor MK886 or
blocking OXER1 signaling via Gue1654 reduced NTEM to that of WT PNs (Fig. 3.5D).
The lipid profile of WT or cPLA2α-KI PNs treated with MK886 showed reduced 5-HETE
and 5-oxo-ETE, but PNs treated with Gue1654 maintained HETE and PGE2 levels similar
to their DMSO-treated controls (Fig. 3.5E), despite having decreased migration equal to
WT cells (Fig. 3.5A).
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Figure 3.5. NTEM and eicosanoid profiles. (A) Neutrophil trans-endothelial migration
(NTEM) between WT, cPLA2α-KI, and cPLA2α-KO PNs. (B) Eicosanoid profile of
cytokine- and chemoattractant-activated neutrophils after 6 hours of NTEM. (C)
Quantification of eicosanoids of interested (e.g., PGE2, 5-HETE, 5-oxo-ETE) after 4 hours
NTEM. (D) NTEM after 4 hours with addition of MK886 (7.5 nM) and Gue1654 (10 µM).
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Figure 3.5 (Continued): (E) Quantification of eicosanoids of interest in WT and KI PNs
with or without MK886 or Gue1654. Analyzed via One-way ANOVA with Tukey’s multiple
comparisons test; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; migration n=6,
eicosanoids n=3-4.

Neutrophil Polarization is Linked to 5-HETE Production and 5-oxo-ETE Metabolism.
Improved healing outcomes correlated with neutrophilia implicates the concept of
neutrophil polarity. Assays for behavioral characteristics of N1 vs N2 neutrophils
demonstrated that the pro-resolution N2 phenotype of reduced NETs, lower ROS, higher
VEGF, and decreased TNFα were displayed by cPLA2α-KI neutrophils, but not WT or
cPLA2α-KO neutrophils (Fig. 3.6A-D). cPLA2α-KI neutrophils showed enhanced
phagocytosis for bacterial removal, which is also enhanced by adding 5-HETE and 5-oxoETE (Fig. 3.6E). Lastly, cPLA2α-KI neutrophils produced less endothelial damage across
all time points evaluated (Fig. 3.6F). Interestingly, only some of the N2-associated
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behaviors could be recapitulated in WT PNs by inhibition or exogenous addition of 5HETE or 5-oxo-ETE (Fig. 3.7). NETosis and ROS production were both increased in
cPLA2α-KI neutrophils by inhibiting 5-HETE production via MK886 or OXER1 signaling
via Gue1654 and could be “rescued” in WT neutrophils by adding 5-HETE or 5-oxo-ETE
(Fig. 3.7A-B). Similarly, pro-resolution VEGF production was positively correlated with the
presence of 5-HETE and 5-oxo-ETE while the inflammatory cytokine TNFα was
negatively correlated with 5-HETE and 5-oxo-ETE production (Fig. 3.7C-D). Interestingly,
only inhibition of OXER1 signaling via Gue1654 had a drastic effect on phagocytosis,
although 5-HETE and 5-oxo-ETE levels did cause mild changes (Fig. 3.7E). Lastly,
endothelial damage after 12 hours was highly correlated with 5-HETE and 5-oxo-ETE
production and signaling (Fig. 3.7F).

Figure 3.6. Neutrophil polarization phenotypes. (A) NETosis Assay after 4 hours using
A23187 neutrophil stimulant. (B) ROS production after 4 hours A23187 challenge. (C)
VEGF production after 4 hours A23187 challenge. (D) TNFα production after 4 hours
A23187 challenge. (E) Bacterial killing assay (E. coli). (F) Syndecan-1 assay for epithelial
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Figure 3.6. (Continued): damage after NTEM at t = 4, 8, 12, and 24 hours (One-way
ANOVA with Tukey post-hoc; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, n=6).

Figure 3.7. Neutrophil behavior with exogenous addition or inhibition of 5-HETE or 5-oxoETE. (A) NETosis Assay after 4 hours A23187 (5 µM). (B) ROS Production Assay after
four hours A23187 (5 µM) (C) Bacterial killing assay (D) VEGF production after 4 hours
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Figure 3.7 (Continued): A23187 (5 µM) (E) TNFα production after 4 hours A23187 (5 µM)
(F) Syndecan-1 assay for endothelial damage after 12 hours NTEM (Student’s t-tests; *p
< 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, n=3-4).

Neutrophil Migration is Linked to the Pentose Phosphate Pathway.
Proteomic analysis of PNs revealed five significant proteins that were differentially
expressed between WT and cPLA2α-KI neutrophils. All five associated genes are linked
to cell metabolism, but PGLS and TMX1, which were both decreased in cPLA2α-KI PNs,
are directly linked to the oxidative branch of the PPP (Fig. 3.8B-C). Western blotting of
naïve and cytokine-challenged PNs confirmed that PGD is significantly decreased in
cPLA2α-KI neutrophils. (Fig. 3.9A-B). ELISA assays for enzymatic activity confirmed that
the compound Physcion at 100 nM could effectively reproduce the cPLA2α-KI PPP
phenotype of decreased PGD without influencing G6PD production (Fig. 3.9C-D). ELISA
assays demonstrated that blocking oxidative PPP activity via PGD inhibitor Physcion
caused WT neutrophils to gain only some of the enhanced cPLA2α-KI phenotypes. WT
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neutrophils treated with Physcion had decreased ROS and TNFα production, and
increased VEGF production (Fig. 3.10B-D). NETosis and endothelial damage was
unaffected by blocking the PPP (Fig. 3.10A&F) and, interestingly, phagocytotic activity
was diminished in cPLA2α-KI neutrophils when PGD was inhibited (Fig. 3.10E).

Figure 3.8. Neutrophil morphology and the PPP. (A) Neutrophil morphology with H&E
staining before challenge and after 6 hours of NTEM. (B) Proteomic analysis of
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Figure 3.8 (Continued): unchallenged WT and cPLA2α-KI neutrophils. Two-way ANOVA
with Dunnett’s multiple comparisons (*p<0.05, **p<0.01, n=5 samples from 5 different
mice). (C) Pentose phosphate pathway (PPP) and its known effects on neutrophil
behavior. Proteins corresponding to those differentially expressed via proteomic
analysis are written in red.

Figure 3.9. PGD is differentially expressed in cPLA2α-KI vs WT neutrophils, which can
be replicated with Physcion. (A) Westerns blotting of neutrophils before challenge and
after 6 hours NTEM. (B) PGD WB densitometry levels in unchallenged and post-NTEM
neutrophils. (C) G6PD and (D) PGD enzyme activity assays ± Physcion (100 nM) in
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Figure 3.9 (Continued): unchallenged PNs (Student’s paired t-tests, n=4). (E) NTEM ±
Physcion (100 nM) (Two-way ANOVA with Dunnett’s multiple comparisons test, n=4). All
data shown as mean ± SD; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.

Figure 3.10. Neutrophil polarization phenotypic markers ± Physcion (100 nM) or a
combination 5-HETE (1.0 nM) and Physcion (100 nM). (A) NETosis Assay after 4 hours
A23187 (5 µM). (B) ROS Production Assay after four hours A23187 (5 µM) (C) Bacterial
killing assay (D) VEGF production after 4 hours A23187 (5 µM) (E) TNFα production after
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Figure 3.10 (Continued): 4 hours A23187 (5 µM) (F) Syndecan-1 assay for endothelial
damage after 12 hours NTEM . All data shown as mean ± SD (Student’s t-tests; *p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001, n=3-4).

C1P/cPLA2α Ablation Causes Neutrophils to Shift to an N2 Phenotype.
Markers to distinguish N1 and N2 neutrophils demonstrated that cPLA 2α-KI PNs
shifted toward a pro-resolution N2 phenotype by 6 hours post-NTEM activation. Cytotoxic
neutrophil marker ICAM-1 increased in WT cells while levels in cPLA2α-KI cells remained
low over time (Fig. 3.11A). Similarly, perfusion recovery marker CXCL10 increased in WT
neutrophils at a significantly higher rate while cPLA2α-KI levels remained lower (Fig.
3.11B). Neutrophil attractant interleukin 8 decreased slightly in WT neutrophils while
cPLA2α-KI levels remained unchanged (Fig. 3.11C). Lastly, chemokine receptor CXCR2
decreased significantly in WT neutrophils while cPLA2α-KI levels remained unchanged
over 6 hours (Fig. 3.11D).
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Figure 3.11. N1 vs N2 markers with or without cytokine/chemokine challenge. (A) ICAM1 adhesion molecule proinflammatory/cytotoxic “N1” neutrophil marker. (B) CXCL10
inflammatory chemokine for perfusion recovery and leukocyte recruitment “N1”
neutrophils marker. (C) IL-8 early neutrophil attractant and activator “N2” neutrophil
marker. (D) CX chemokine receptor 2 (CXCR2) “N2” neutrophil marker.
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Discussion
Previously published research from our lab showed an enhanced acute healing
outcome for our cPLA2α-KI GEMM (MacKnight et al. 2019). Specifically, wound
maturation occurred in a more rapid manner as characterized by enhancement of the
proliferation and remodeling stages. Thus, we attempted to examine the inflammatory
phase of wound healing to see if there were any improvements in cPLA 2α-KI mice.
Surprisingly, we observed elevated neutrophils in the wound site at earlier time points for
longer periods of time (Fig. 3.2) contrary to our expectations since neutrophilia is
commonly association with poor healing outcomes (Wang et al. 2019). Additionally, we
observed neutrophil-mediated inflammation in cPLA2α-KI mice in an E. coli model of
peritoneal infection (Fig. 3.3 A) and increased survival in sepsis (Fig. 3.3 B). In vivo
imaging fluorescence data was confirmed via IHC at 6-hours post-injury that cPLA2α-KI
mice relied heavily on neutrophil-mediated inflammation as indicated by elevated Ly6G+
cells present in tissue samples, and WT mice relied heavily on macrophage-mediated
inflammation as evident by increased CD68+ and F4/80+ cells (Figure 3.4) These
unexpected positive outcomes demonstrate what we term as the “neutrophil conundrum.”
Thus, we set out to evaluate i) which pathways are responsible for this enhanced
neutrophil recruitment, and ii) how cPLA2α-KI neutrophils differ phenotypically or
behaviorally that allows them to persist in wound sites without causing excessive cytokine
storm or host tissue damage.
First, we compared WT neutrophils to both cPLA2α-KI and cPLA2α-KO neutrophils
since cPLA2α-KO mice did not show the same wound healing improvements as cPLA 2αKI mice despite decreased PGE2 production (MacKnight et al., 2019). We observed that
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cPLA2α-KI neutrophils migrated through an endothelial layer more than 3 times faster
than both WT and KO cells (Fig. 3.5 A). Interestingly, the eicosanoid profile of these
neutrophils was remarkably similar to the fibroblast profile of elevated 5-HETE and 5-oxoETE with decreased PGE2 (Fig. 3.5 B&C). As such, this enhanced cPLA2α-KI migration
could be subdued, either by inhibiting 5-HETE production via FLAP inhibitor MK886, or
by blocking OXER1 signaling via Gue1654 (Fig. 3.5D). As expected, MK886 reduced 5HETE and 5-oxo-ETE levels to that of WT cells, but Gue1654 did not significantly lower
5-HETE or 5-oxo-ETE levels despite its suppressive effect on NTEM (Fig. 3.5E). Thus,
neutrophil migration enhancement appears to be specifically dependent on OXER1
signaling via 5-oxo-ETE.
To identify phenotypic differences in neutrophils, we quantified various behavioral
components in WT, cPLA2α-KI, and cPLA2α-KO cells. NET and ROS production, while
effective in eliminating pathogens, can also be cytotoxic and exacerbate sepsis and organ
dysfunction (Kumar et al. 2021). Likewise, while TNFα is responsible for a diverse range
of cellular signaling events, it is typically indicative of macrophage-mediated inflammatory
response (Wu et al. 2015) and may contribute to oxidative stress (Tsutamoto et al. 2001).
Thus, it was interesting to see that cPLA2α-KI neutrophils uniquely demonstrated low
levels of NETosis, ROS, and TNFα compared to both WT and cPLA2α-KO cells (Fig. 3.6A,
B, D). Furthermore, cPLA2α-KI neutrophils promote angiogenesis via elevated VEGF
production (Fig. 3.6C) and appear to be more dependent upon phagocytosis for bacterial
removal than other techniques that cause more collateral damage (e.g., ROS) (Fig. 3.6E).
Since cPLA2α-KI neutrophils and fibroblasts both demonstrate an eicosanoid
profile high in 5-HETE and 5-oxo-ETE, we attempted to inhibit and rescue neutrophil
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behaviors using small molecule inhibitors (Fig. 3.7). Remarkably, all cPLA 2α-KI
phenotypic behaviors could be recapitulated in WT neutrophils by adding 5-HETE or 5oxo-ETE. Likewise, all cPLA2α-KI phenotypes could be reduced to WT levels by inhibiting
5-HETE production or OXER1 signaling via 5-oxo-ETE. Of note, phagocytosis was
especially sensitive to OXER1 inhibition. While MK886 significantly reduced phagocytotic
activity in cPLA2α-KI cells, Gue1654 was able to reduce WT and cPLA2α-KI phagocytosis
to extremely low levels (Fig. 3.7E), again suggesting high dependence on 5-oxoETE/OXER1 signaling.
Neutrophils from WT and cPLA2α-KI mice also have slight differences in
morphology. WT cells have larger, more granulated nuclei while cPLA2α-KI cells have
narrow, tubular nuclei (Fig. 3.8A). Mature neutrophils often display toxic granulation in
response to hyperinflammation or infections conditions and are often used as a surrogate
marker for underlying infection or inflammation (va de Vyver et al. 2010). Proteomic
analysis indicated cPLA2α-KI neutrophils had decreases in PGLS, linked to the oxidative
branch of the PPP, and Tmx1, linked to cell response to oxidative stress (Fig. 3.8B). The
PPP regulates various neutrophil behaviors such as NETosis, ROS production, and
phagocytosis (Fig. 3.8C), and thus because a focus of this research. The PGLS gene
generates the enzyme gluconolactonase responsible for the production of 6phosphogluconate dehydrogenase (PGD), the second of two NADPH-producing
enzymes in the oxidative PPP. Indeed, PGD levels were significantly decreased in
cPLA2α-KI neutrophils before or after chemokine challenge (Fig. 3.9A&B).
We then attempted to recapitulate the cPLA2α-KI phenotype by inhibiting PGD with
a compound called Physcion, which produces a hydrophobic interaction with PGD at
93

Met15 site (Ghanem et al. 2021). Interestingly, Physcion has been reported previously as
having anti-inflammatory (Ghosh et al., 2010) and anti-microbial activities (Tamokou et
al., 2009). Physcion was able to effectively reduce PGD activity while leaving G6PD
activity unchanged (Fig 3.9C&D). However, modulation of the PPP alone was unable to
enhance WT NTEM to that of cPLA2α-KI neutrophils (Fig 3.9E), indicating a 5-HETE or
OXER1 dependence. Similarly, Physcion alone was unable to decrease NETosis or
endothelial damage in WT cells (Fig 3.10A&F), although it was able to reduce ROS and
TNFα production and increase VEGF production to that of cPLA2α-KI levels (Fig 3.10BD). Interestingly, Physcion alone reduced cPLA2α-KI phagocytosis to that of WT
neutrophils, but this loss was overcome by a combination of Physcion and 5-HETE. Thus,
neutrophil behaviors of ROS, TNFα, and VEGF production can be tilted in favor of an antiinflammatory phenotype by decreasing PGD via Physcion, while NETosis and Syndecan1 levels remain unchanged and phagocytosis is decreased. Interestingly all neutrophil
phenotypes analyzed in this study could be tilted toward pro-resolution outcomes by
adding 5-HETE or 5-oxo-ETE and phagocytosis uniquely demonstrated a rigid
dependence upon OXER1 signaling (Fig 3.12).

Figure 3.12. Schematic representation of lipid profile high in 5-HETE and 5-oxo-ETE
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Figure 3.12 (Continued): causing decreases in PGD and PPP-produced superoxide
resulting in decreased TNFα, ROS, and an increased VEGF. This lipid profile also
correlates with decreased endothelial damage, increased neutrophil phagocytosis, and
elevated NTEM by some other as of yet unidentified mechanism.

Lastly, the observed phenotypic differences in neutrophils were linked to neutrophil
polarization (N1 vs N2) via specific cell surface markers (Fig 3.11). Intercellular adhesion
molecule-1 (ICAM-1) can be expressed in a cell-specific manner by several cytokines
(e.g., IL-1, TNFα) (Tosi et al. 1992) and often indicates promotion of pro-inflammatory
leukocytes to sites of infection (van de Stople & van der Saag 1996). After 6 hours NTEM,
ICAM-1 increased nearly 50% in WT neutrophils while remaining relatively unchanged in
cPLA2α-KI cells (Fig 3.11A). Interestingly, ICAM-1 is cleaved in a dose-dependent
manner by neutrophil elastase in humans (Champagne et al. 1998), which correlates to
the slightly elevated neutrophil elastase present in wound tissue of cPLA2α-KI mice (Fig
3.4). Similarly, IFN-γ-inducible protein-10 (CXCL10) is produced in response to oxidative
injury in a positive feedback manner (Zhang et al. 1998). In fact, antibodies to CXCL10
have been found to reduce neutrophil recruitment to oxidative stress-induced neutrophilic
airway inflammation by up to 72% (Michalec et al. 2002). While both WT and cPLA 2α-KI
neutrophils showed increases in CXCL10 over 6 hours, cPLA2α-KI cells produced
significantly less CXCL10 (Fig 3.11B), despite having more active neutrophil recruitment
according to the NTEM migration percentages (Fig 3.5A).
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For markers of anti-inflammatory N2 neutrophils, we first examined the chemokine
interleukin-8 (IL-8). Unlike ICAM-1 which is initiated by pro-inflammatory cytokines, IL-8
is a neutrophil attractant produced by mononuclear phagocytic cells and other noninflammatory cells (Kunkel et al. 1991). While some research suggests that IL-8 can itself
cause neutrophil-dependent tissue damage (Harada et al. 1994), recent work in tumor
identification has established IL-8 as a standard pro-resolution N2 marker that enhances
the immunosuppressive microenvironment (David et al. 2016; Ohms et al. 2020). WT
neutrophils decreased IL-8 production after 6 hours of NTEM while cPLA2α-KI neutrophils
maintained steady levels of the chemokine (Fig. 3.11C). This data correlates to the
continued recruitment of neutrophils into the wound site despite lower levels of
inflammatory cytokine. Likewise, C-X-C motif chemokine receptor 2 (CXCR2) decreased
significantly over time in WT neutrophils but remained steady in cPLA 2α-KI cells (Fig.
3.11D). CXCR2 ligands (e.g., CXCL1, CXCL2/3) are chemotactic for neutrophils, thus
CXCR2 is thought to recruit neutrophils without the presence of cytokines with proinflammatory properties (Reutershan et al. 2006). This fortifies our IL-8 findings that
cPLA2α-KI neutrophils can recruit more neutrophils to a wound more rapidly without
incurring a hyperinflammatory cytokine storm resulting in tissue damage. Indeed, work in
bovine models demonstrated elevated CXCR2 corresponded to increased neutrophil
phagocytosis of bacterial pathogens (Rembeaud & Pighetti 2005), which our data would
suggest is potentially reliant upon OXER1 receptor signaling. However, the existing
research on N1 and N2 polarization is not unanimous on phenotypic observations. For
instance, murine tumor models recently suggested that neutrophils high in CXCR2 and
IL-8 had a decreased ability to kill parasitic protozoa (Ohms et al. 2020). Thus, the
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complex microenvironment appears to influence neutrophil behavior in a manner that
requires further understanding. However, the data presented in this chapter strongly
suggest 5-HETE/5-oxo-ETE metabolism and OXER1 signaling are potent regulators of
neutrophil behavior that “tips the scale” toward pro-resolution mechanisms of pathogen
removal, allowing acute wounds to progress to proliferation and remodeling stages at a
much faster rate.

Limitations
One limitation of this study is the novelty of the field of neutrophil polarization and
its lack of consensus on identifying factors and causal mechanisms for N1 versus N2.
Much of the current literature focuses on neutrophil behaviors in the tumor environment
which may not translate properly to the wound healing milieu. Of note, a reperfusion
marker like CXCL10 will likely be expressed very differently in these two situations,
leading to a lack of consistency in categorizing an N1 or N2 neutrophil. Additionally, the
morphological changes in neutrophils between WT and KI mice may play a more crucial
role in identifying polarity or age (and thus behavior) than our lab has the capability of
diagnosing. We are considering seeking histological and hematological expertise to better
characterize our cytospin microscopy observations. Furthermore, we acknowledge the
lack of a clear link between PGD expression and HETE biosynthesis. Hence, a major
future direction is designing a series of experiments to determine if the PPP influences
HETE production, vise versa, or neither. And if the two are not connected, why is PGD
clearly and repeatably subdued in our KI mice? Lastly, we acknowledge that beneficial
phenotypic results from a genetic ablation have limited clinical application, as it’s nearly
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impossible to replicate via medication. However, we think this research is an important
pre-clinical first step because it shows clear evidence of improvements to wound healing
and sepsis outcomes correlated with consistent changes in lipid profiles.
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CHAPTER FOUR: DISCUSSION AND CONCLUSIONS

Significance
One of the more important aspects of the studies presented in this dissertation is
the demonstration of defined mechanistic roles of lipid:protein interactions in vivo. To our
knowledge, this is the first time a repeatable “lipid fingerprint” of elevated 5-HETE and 5oxo-ETE has demonstrated compression of both inflammatory and proliferative stages of
mammalian wound healing reliant upon OXER1 cell signaling. Of note, this eicosanoid
profile could be repeated in vivo by inhibiting an upstream mediator, ceramide kinase, by
oral administration of a novel inhibitor after the point of wounding. These findings open
the door for targeted therapeutic interventions to provide a temporal shift in cPLA 2α
function in cells responding to inflammatory agonists without the need for genetic ablation
or pre-wound administration. Furthermore, we’ve presented strong evidence of a “class
switch” in cPLA2α function with a measurable effect on the pentose phosphate pathway
and neutrophil polarization toward a pro-resolution “N2” phenotype. This evidence
suggests the potential for eicosanoid balance to “tip the scales” from hyperinflammatory
physiologies (e.g., chronic wounds and sepsis) toward healing and improved survival
without sacrificing pathogen removal.
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Future directions
While these studies greatly expanded the understanding of the C1P/cPLA 2α
interaction in the wound healing milieu, further study is still required to fully elucidate the
potential of the C1P/cPLA2α and 5-oxo-ETE/OXER1 axes. One question that remains is,
does cPLA2α interact with a lower-affinity lipid in the absence of C1P? Previous work from
our lab has suggested that perhaps cPLA2α shifts to a calcium-independent role such as
PIP2 interaction (Stephenson et al. 2017), but these studies have yet to be performed.
Additionally, we demonstrated that post-injury oral administration of CERK inhibitor
SYR382141 was able to improve account wound healing phenotypes, but the next step
would be to test a topical salve or combination ointment which could provide a directed
dose of inhibitor directly to the wound site. Indeed, PO b.i.d. administration of CERK
inhibitor did have negative effects on the overall health of the animals (e.g., weight loss).
In the area of neutrophil polarization, there is still much to explore. One objective
would be to measure G-CSF levels in neutrophils, as toxic granulation is often induced
by granulocyte colony-stimulating factor (G-CSF) which become detectable in the serum
as bone marrow-derived granulocyte precursors activate mature neutrophils (Kabutomori
et al. 2000). These studies may better explain the slight morphological differences
between WT and cPLA2α-KI neutrophils. Similarly, we’ve shown certain aspects of
neutrophil polarization regulated by the PPP and others regulated by the 5-oxoETE/OXER1 axis, but further studies are needed to identify the causal links between
these two distinct pathways.
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Concluding Remarks
The studies presented here help to bolster over a decade of research in enzyme
kinetics, biophysical analyses, and cellular assays to elucidate the various mechanisms
of C1P production and interaction with cPLA2α, and the resulting shift in eicosanoid
generation in physiological contexts. In recent years our lab has highlighted the
importance of cPLA2α localization and its influence on cell migration, the importance of
combination therapy (e.g., lowering PGE2 and increasing HETEs), and the potential for
alternate attenuations of the sphingosine rheostat. The research presented in this
dissertation has contributed significantly to the modern corpus of lipidomic work by
identifying the importance of a downstream metabolite, 5-oxo-ETE, and a receptor not
previously categorized in murine models, OXER1. Similarly, we’ve presented for the first
time a direct link between the 5-oxo-ETE/OXER1 axis and neutrophil polarization. When
examined as a whole, these data clearly indicate a significant role for intracellular C1P
production via CERK, the C1P/cPLA2α interaction, substrate specificity and colocalization, and the interplay between eicosanoid production and the oxidative PPP.
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